SUPPRESSION OF ANTI-TUMOR IMMUNITY IN CHRONIC LYMPHOCYTIC LEUKEMIA VIA INTERLEUKIN-10 PRODUCTION by Alhakeem, Sara
University of Kentucky 
UKnowledge 
Theses and Dissertations--Microbiology, 
Immunology, and Molecular Genetics 
Microbiology, Immunology, and Molecular 
Genetics 
2017 
SUPPRESSION OF ANTI-TUMOR IMMUNITY IN CHRONIC 
LYMPHOCYTIC LEUKEMIA VIA INTERLEUKIN-10 PRODUCTION 
Sara Alhakeem 
University of Kentucky, sal237@uky.edu 
Digital Object Identifier: https://doi.org/10.13023/ETD.2017.406 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Alhakeem, Sara, "SUPPRESSION OF ANTI-TUMOR IMMUNITY IN CHRONIC LYMPHOCYTIC LEUKEMIA VIA 
INTERLEUKIN-10 PRODUCTION" (2017). Theses and Dissertations--Microbiology, Immunology, and 
Molecular Genetics. 16. 
https://uknowledge.uky.edu/microbio_etds/16 
This Doctoral Dissertation is brought to you for free and open access by the Microbiology, Immunology, and 
Molecular Genetics at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Microbiology, 
Immunology, and Molecular Genetics by an authorized administrator of UKnowledge. For more information, please 
contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained needed written permission statement(s) 
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine) which will be 
submitted to UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s thesis including all 
changes required by the advisory committee. The undersigned agree to abide by the statements 
above. 
Sara Alhakeem, Student 
Dr. Subbarao Bondada, Major Professor 
Dr. Ken Fields, Director of Graduate Studies 
 
 
SUPPRESSION OF ANTI-TUMOR IMMUNITY IN CHRONIC LYMPHOCYTIC 
LEUKEMIA VIA INTERLEUKIN-10 PRODUCTION 
 
 
 
 
 
 
 
DISSERTATION 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy in the College of Medicine at the University of Kentucky 
 
By 
 
Sara Samir Alhakeem 
 
Lexington, Kentucky 
 
Director: Dr. Subbarao Bondada, PhD 
 
Professor of Microbiology, Immunology and Molecular Genetics 
 
University of Kentucky, Lexington, Kentucky 
 
2017 
 
Copyright © Sara Samir Alhakeem 2017
 
 
ABSTRACT OF DISSERTATION 
 
 
 
 
SUPPRESSION OF ANTI-TUMOR IMMUNITY IN CHRONIC LYMPHOCYTIC 
LEUKEMIA VIA INTERLEUKIN-10 PRODUCTION 
 
 The most common human leukemia is B-cell chronic lymphocytic leukemia 
(B-CLL), which is characterized by a progressive accumulation of abnormal B-
lymphocytes in blood, bone marrow and secondary lymphoid organs. Typically 
disease progression is slow, but as the number of leukemic cells increases, they 
interfere with the production of other important blood cells, causing the patients 
to be in an immunosuppressive state. To study the basis of this 
immunoregulation, we used cells from the transgenic Eμ-TCL1 mouse, which 
spontaneously develop B-CLL due to a B-cell specific expression of the 
oncogene, TCL1. Previously we showed that Eμ-TCL1 CLL cells constitutively 
produce an anti-inflammatory cytokine, IL-10. Here we studied the role of IL-10 in 
CLL cell survival in vitro and the development of CLL in vivo. We found that 
neutralization of IL-10 using anti-IL-10 antibodies or blocking the IL-10 receptor 
(IL-10R) using anti-IL-10R antibodies did not affect the survival of CLL cells in 
vitro. On the other hand, adoptively transferred Eμ-TCL1 cells grew at a slower 
rate in IL-10R KO mice vs. wild type (WT) mice. There was a significant reduction 
in CLL cell engraftment in the spleen, bone marrow, peritoneal cavity and liver of 
the IL-10R KO compared to WT mice. Further studies revealed that IL-10 could 
be playing a role in the tumor microenvironment possibly by affecting anti-tumor 
immunity. This was seen by a reduction in the activation of CD8+ T cells as well 
as a significantly lower production of IFN-γ by CD4+ T cells purified from CLL-
injected WT mice compared to those purified from CLL-injected IL-10R KO mice. 
Also CLL-primed IL-10R null T cells were more effective than those from similarly 
CLL-primed wild type mice in controlling CLL growth in immunodeficient recipient 
mice. These studies demonstrate that CLL cells suppress host anti-tumor 
immunity via IL-10 production. This led us to investigate possible mechanisms by 
which IL-10 is produced. We found a novel role of B-cell receptor (BCR) signaling 
pathway in constitutive IL-10 secretion. Inhibition of Src or Syk family kinases 
reduces the constitutive IL-10 production by Eμ-TCL1 cells in a dose dependent 
manner. We identified the transcription factor Sp1 as a novel regulator of IL-10 
production by CLL cells and that it is regulated by BCR signaling via the 
Syk/MAPK pathway. 
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CHAPTER 1 
Introduction 
 B-cell malignancies represent a diverse collection of diseases, including 
non-Hodgkin’s lymphomas (NHLs) and Hodgkin’s lymphoma [1]. NHLs are a 
heterogeneous group of more than 30 cancers that include chronic lymphocytic 
leukemia (CLL), which mainly affects B lymphocytes [1]. In the United States, B 
cell lymphomas represent 80-85% of all NHL cases, with 15-20% being T-cell 
lymphomas [1]. Regarding these B-cell lymphomas, diffuse large B-cell 
lymphoma (DLBCL) has the highest incidence of 30%, followed by follicular 
lymphoma (20%) [1]. NHL and leukemia are the seventh and eleventh most 
common neoplasms, respectively, in the US, with CLL accounting for about one 
third of all leukemia cases [1, 2]. 
	 B cell Chronic lymphocytic leukemia is a clinically heterogeneous disease 
originating from B lymphocytes that may differ in activation or maturation state 
[3]. Although CLL is rare in some countries, such as Japan and Korea, it is the 
most common adult leukemia in the Western world [4]. CLL is a disease of the 
elderly but has also been seen in younger adults [2]. CLL cells originate from 
clonal expansion of mature B cells expressing the T-cell marker CD5 [3]. The 
disease is defined by abnormal lymphocytes produced in the bone marrow that 
have defects in apoptosis, or other cell death mechanisms, leading to the 
accumulation of small, mature-appearing neoplastic lymphocytes in the blood, 
bone marrow and secondary lymphoid tissues, resulting in lymphocytosis, 
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leukemia cell infiltration of the marrow, lymphadenopathy and splenomegaly [3, 
4]. Leukemic cell accumulation occurs because of survival signals delivered to 
the cells from the external environment through a number of receptors (e.g., B-
cell receptors and chemokine and cytokine receptors) and their cell-bound and 
soluble ligands. B cell receptor (BCR) signaling influences the behavior of 
chronic lymphocytic leukemia, where engagement of surface immunoglobulin by 
antigen has been shown to be a key driver of CLL cells with outcome influenced 
by the nature of the cell, the level of stimulation and the microenvironment [5]. 
CLL patients are subdivided into two groups, those with mutations in the 
immunoglobulin variable heavy chain (IGVH) and those without mutations in the 
IGVH [3]. CLL cells that express an unmutated IGHV (U-CLL) originate from a B 
cell that has not undergone somatic hypermutation in germinal centers [4]. CLL 
cells with mutated IGHV (M-CLL), arise from a post-germinal center B cell that 
expresses immunoglobulin, which has undergone somatic hypermutation and, in 
some cases, also immunoglobulin isotype switching [4]. Patients with CLL cells 
that express an unmutated IGHV typically have more-aggressive disease than 
patients with CLL cells that express a mutated IGHV [6]. Other characteristics 
such as expression of TCL1, ZAP70 and CD38 proteins are broadly associated 
with poor prognosis [6-9]. 
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(1a) Epidemiology, diagnosis and clinical features of CLL 
 Chronic lymphocytic leukemia is more common in adults and more 
common among men than women, particularly Caucasian men (Figure 1.1) [10]. 
 
 The number of new cases of CLL was 4.7 per 100,000 men and women 
per year based on 2010-2014 cases [10]. In 2017, it is estimated that there will 
be 20,110 new cases of chronic lymphocytic leukemia and an estimated 4,660 
people will die of this disease (Figure 1.2) [10].  
  
Figure 1.1: Percent of new cases of CLL by age group. 
Adapted from SEER Cancer Stat Facts: Chronic Lymphocytic Leukemia. National Cancer Institute. 
Figure 1.2: Epidemiology of chronic lymphocytic leukemia at a glance. 
Adapted from SEER Cancer Stat Facts: Chronic Lymphocytic Leukemia. National Cancer Institute. 
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 Diagnosing CLL is based on differential blood count, flow cytometry of the 
peripheral blood to determine the immunophenotype of circulating lymphocytes, 
and examination of the peripheral smear [11]. The National Cancer Institute 
guidelines require two criteria to be met for the diagnosis of CLL. 1) Absolute B 
lymphocyte count in the peripheral blood should be ≥5000/μl [5 x 109/L], with the 
appearance of a population of morphologically mature-appearing small 
lymphocytes [11]; 2) Demonstration of clonality of the circulating B cells by flow 
cytometry. The majority of the population should express the following pattern of 
B cell markers: low levels of surface immunoglobulins (CD20 and CD79b), and 
either kappa or lambda (but not both) light chains, expression of B cell 
associated antigens (CD19, CD20, and CD23) and expression of the T cell 
associated antigen CD5 [11]. In addition, although a bone marrow test is 
normally not required for CLL initial diagnosis or confirmation, it is commonly 
performed to establish a baseline to measure response to therapy [2, 11]. A 
baseline bone marrow test for CLL patients often establishes an increase in the 
number of B lymphocytes and a decrease in the number of normal marrow cells 
[2]. How the cells are clustred in the bone marrow can also classify them into one 
of four kinds of CLL cell patterns; nodular, interstitial, mixed or diffused [2]. 
 The majority of CLL patients are asymptomatic at diagnosis and CLL is 
often found based on routine blood counts. Otherwise, patients may present with 
swollen lymph nodes, splenomegaly, fatigue, fever, weight loss and night sweats 
[2]. Many of the signs and symptoms of advanced CLL occur because the 
leukemic cells replace the normal blood cells. Therefore, patients can suffer from 
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anemia due to low red blood cell count, bleeding and bruising due to shortage of 
platelets and an increase in infections due to lower normal white blood count [2]. 
Moreover, systemic immunosuppression has been found to be associated with a 
more aggressive CLL disease and secondary cancers such as skin cancer, head 
and neck cancer, and lymphoblastic leukemia [12]. This immunosuppression 
increases susceptibility to infection, which is the leading cause of death in CLL 
patients [13-15]. Patients with CLL are at risk for infection for a variety of 
reasons.  CLL patients have inherent immune defects in humoral, as well as cell-
mediated immunity, which are related to the primary disease process. These 
defects include hypogammaglobulinaemia, abnormalities in T cell subsets and 
defects in complement activity and neutrophil/monocyte function [13, 16]. In 
addition, specific immunodeficiencies related to therapies administered to 
patients can result in additional immunosuppression [13]. 
(1b) Clinical staging and treatment of CLL 
 Two clinical staging systems are widely used for classifying CLL patients 
into three broad prognostic groups [4]. The Rai staging system is more 
commonly used in the United States, whereas the Binet classification is more 
commonly used in Europe [4]. The staging systems each recognize the 
importance of bone marrow function and define late-stage or high-risk disease by 
the presence of pronounced anemia or thrombocytopenia [4]. Table 1.1 and 
Table 1.2 summarize both classifications.  
  6 
 
 
 Patients with CLL can manage their disease with their physicians for years 
with observation, which is referred to as the wait-and-watch method [2]. The 
watch-and-wait approach is the standard care for patients who are considered 
low-risk with slow growing disease, minimal changes in their blood counts and no 
symptoms [2]. Since no treatment to date has made a significant impact on the 
outcome of patients with early-stage CLL, when to initiate therapy becomes an 
Table 1.1: CLL Rai staging system 
Kipps, T.J., et al., Chronic lymphocytic leukaemia. Nat Rev Dis Primers, 2017. 3: p. 16096. (reporoduced with 
permission from Nature). 
Table 1.2: CLL Binet staging system 
Kipps, T.J., et al., Chronic lymphocytic leukaemia. Nat Rev Dis Primers, 2017. 3: p. 16096. (reporoduced with 
permission from Nature). 
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important decision. Generally, indications to initiate therapy include pronounced 
disease related anemia or thrombocytopenia as well as symptoms that are 
associated with active disease, such as night sweats, fatigue, weight loss and 
fever with no apparent infection [4]. For patients in need of treatment, a number 
of factors play a role in the choice of treatment. Briefly, patients with del(17p) or 
mutated TP53 are treated with therapy that does not require functional TP53, 
such as ibrutinib (Bruton tyrosine kinase (BTK) inhibitor) [4]. For patients without 
these mutations, IGHV mutational status can help define the treatment strategy 
[4]. Patients with unmutated IGHV are often considered for therapy with ibrutinib 
as CLL cells with unmutated IGHV seem to be more sensitive to inhibitors of 
BCR signaling than CLL cells with mutated IGHV [4]. Patients with mutated IGVH 
are good candidates for chemoimmunotherapy as they have excellent outcomes 
with this regimen, such as fludarabine, cyclophosphamide and rituximab (anti-
CD20 antibody), with >50% of patients having a median progression-free survival 
of >10 years [4]. Patients who develop de novo del(17p) or TP53 mutations or 
who develop resistance or intolerance to ibrutinib are often considered for 
therapy with idelalisib (phosphoinositide 3-kinase (PI3K) inhibitor) and rituximab 
or the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax [4]. Patients who develop 
resistance or intolerance to inhibitors of BTK, PI3K and/or BCL-2 are considered 
for clinical trials or alternative agents [4]. 
(1c) Cellular origin of CLL 
 A number of cell types have been suggested to give rise to CLL, with no 
consensus as to the normal counterpart of CLL cells [17]. The debate 
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surrounding the cellular origin of CLL cells mainly arise from the heterogeneity 
found in the disease. For example, the use of both unmutated and mutated IGVH 
genes, which as mentioned earlier distinguishes CLL patient subgroups, gave 
rise to a 2-cell origin model in which the 2 subgroups of CLL originated from 
distinct cell types [17]. In support of this theory, B cell receptor signaling has 
been found to be a promoting factor that could lead to differing cell biology and 
patient pathology.[17] For instance, since the development of IGVH gene 
mutations requires BCR crosslinking, then CLL cases that exhibit IGVH gene 
mutations must have ascended from previously stimulated B cells. Therefore, the 
CLL cells without IGVH gene mutations would have possibly originated from 
naïve B cells [5]. But the fact that absence of IGVH gene mutations does not 
necessary mean the lack of prior antigen stimulation, the cases of U-CLL could 
simply be derived from antigen-stimulated B cells that didn’t accumulate 
mutations [5]. Chiorazzi et al, hypothesize that the lack of mutations in those 
cases could either be a consequence of the type of antigenic stimulation that the 
cell received (e.g., T-independent) or a result of the timing of the transformation 
event (e.g., occurred before a germinal center (GC) founder cell entered a GC) 
[5].  
 On an opposing note, other studies utilizing gene expression analysis 
revealed only a small number of differences between genes expressed in U-CLL 
and M-CLL, which suggested a one-cell originating model for CLL [18, 19]. In that 
case, the difference in cellular features and clinical outcomes between U-CLL 
and M-CLL could be accounted for possibly by additional promoting factors. To 
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bring together the 2-cell origin model, which is more consistent with BCR 
findings, with the one-cell model, supported by gene expression data, a new 
theory was proposed in which both U-CLL and M-CLL derive from marginal zone 
(MZ) B cell [3, 5]. This unifying theory arose due the similarity between MZ B 
cells and CLL cells. MZ B cells (IgMhighIgDlow) respond to bacterial 
polysaccharides in a T cell-independent manner [20]. They can express either 
mutated or unmutated IGVHs [21]. Also, evidence suggest that MZ B cells may 
accumulate IGVH gene mutations outside of classical GC, possibly in the MZ 
itself, which would provide an explanation to a continuous accumulation of such 
mutations in some CLL cases [5, 17, 22]. However, despite the similarities found 
between MZ B cells and CLL cells, an MZ origin for CLL still faces some 
reservations. MZ B cells express surface IgM and IgD as most CLL clones do, 
however; they are CD5-CD23-CD22+, which is a surface phenotype different than 
that of a CLL cell [20]. It has been shown that up-regulation of CD5 and CD23 
could occur upon activation of cells, which could reflect this phenotypic difference 
[23, 24]. Since comparisons of surface phenotypes of malignant and normal B 
cells are often used to identify normal counterparts in hematological 
malignancies, challenges remain in considering MZ B cells as the normal 
counterpart of CLL. 
 Another possible cellular origin of CLL is a unique subset of B cells called 
B-1 cells. B-1 cells unlike MZ B cells express the T cell marker CD5 [25-27]. B-1 
cells express IgM, low levels of CD23 and unmutated IGVH genes [28, 29]. 
Another unique feature of B-1 cells is the secretion of polyreactive and natural 
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antibodies [28, 29]. Murine B-1 cells are predominantly found in the peritoneal 
and pleural cavities and only constitute 1-2% of splenic B cells [29, 30]. Unlike 
conventional B-2 cells, which are produced continuously in the bone marrow, 
mouse B-1 cells are generated only from hematopoietic stem cells in the fetal 
liver or in the bone marrow the first few weeks after birth and are subsequently 
maintained by self-renewal in the periphery [28, 30]. Recently, a specific B-1 cell 
restricted progenitor (Lin-CD45Rlo/-CD19+ cells) in the bone marrow has been 
identified, which preferentially reconstituted B-1 cells but not B-2 cells, in vivo 
[31, 32]. Like murine B-1 cells, the antigen specificities of CLL BCRs are more 
polyreactive, which allows the cells to bind autoantigens and therefore secrete 
natural autoantibodies [33-35]. Since developing B cells are naturally 
autoreactive until antigen-driven clonal selection and somatic IGVH mutations 
during GC reactions [36], U-CLL cases have the greater level of polyreactivity 
and autoreactivity than M-CLL [37]. However, if M-CLL gene rearrangements are 
reverted back to the germline sequence, antibodies produced by the cells can 
display polyreactivity [17, 37, 38]. In support of B-1 cell as the cellular origin of 
CLL Hayakawa et al. was able to demonstrate that early generated B-1 B cells 
with distinct BCRs can become CLL in aging mice [39]. They identified an 
unmutated BCR in mouse that is autoreactive with non-muscle myosin IIA 
(AMyIIA) [39]. B cells with this AMyIIA BCR are generated by BCR signaling 
during B-1 fetal and neonatal development [39]. These early generated B-1 cells 
can self-renew, increase during aging and can progress to aggressive CLL in 
aged mice [39]. Interestingly, BCRs autoreactive to AMyIIA are also commonly 
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seen in some human CLLs [39]. In a follow up study, they showed that B-1 B 
cells with other stereotyped BCRs commonly found in mouse CLL can generate 
CLL [40]. More importantly, the progression to CLL by B-1 B cells is not only a 
result of their ability to express specific BCRs because CLL did not develop from 
other B cell subsets even with BCRs identical to the ones on B-1 cells, 
suggesting that both specific BCRs and B-1 cell environment were important for 
CLL progression [40]. 
 Regardless of the comparable nature between B-1 and CLL cells, human 
B cells with characteristics of murine B-1 cells have not been identified. Although 
human CD5+ B cells exist in the circulation, the majority of these cells do not 
exhibit features expected of B-1 cells [5, 41]. For example, IgM antibodies 
produced by CD5+ cells in adult human blood are usually not polyreactive, 
although coded by unmutated IGHVs [42]. In addition, human CD5+ B cells do 
not proliferate when stimulated with T-cell independent antigens [17, 43]. 
However, in a recent study Griffin et al. described a 
CD20+CD27+CD43+CD70− subset present in adult and human cord blood with 
functional characteristics that would describe murine B-1 cells [44]. These cells 
spontaneously secrete IgM, maintain constitutive BCR signaling and are able to 
drive allogeneic T cell proliferation [44]. Further studies need to be performed to 
completely understand this cell subset and if it can be identified as the cellular 
origin of CLL in human patients. 
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(1d) Immunosuppression and other risks in CLL 
 Patients with CLL have an increased risk of other medical conditions such 
as infections, autoimmune diseases, or secondary cancers. Infections in CLL 
patients have been recognized as a common cause of morbidity and mortality 
[13-15]. The risk of infection increases with the increase of CLL duration. In 
addition, the new encouraging therapeutics in CLL often come at the cost of 
serious opportunistic infections [15]. In early, untreated CLL, patients infection 
risk is mainly related to hypogammaglobulinemia [15]. Infections by encapsulated 
bacteria are also common in such a setting [15]. On the other hand, patients with 
advanced CLL will mostly suffer from neutropenia and defects in cell-mediated 
immunity. A large variety of pathogens, including Listeria monocytogenes, 
mycobacteria, opportunistic fungi, Pneumocystis carinii and herpesviruses are 
seen in advanced CLL patients [15]. Pathogens seen frequently in CLL patients 
undergoing different therapeutic regimens are listed in Table 1.3 [15]. In addition, 
Table 1.4 describes some of the predominant immune defects found in different 
stages of CLL [15].  
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  Table 1.3: Frequent pathogens seen in chronic lymphocytic leukemia 
patients undergoing different treatment regimens 
Tsiodras, S., Samonis, G., Keating, M.J. & Kontoyiannis, D.P. Infection and immunity in chronic lymphocytic 
leukemia. Mayo Clin Proc 75, 1039-1054 (2000). (Reproduced with permission from Mayo Clinic Proc.). 
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Tsiodras, S., Samonis, G., Keating, M.J. & Kontoyiannis, D.P. Infection and immunity in chronic lymphocytic 
leukemia. Mayo Clin Proc 75, 1039-1054 (2000). (Reprodcued with permission from Mayo Clinic Proc.). 
Table 1.4: Immune defects found in different stages of chronic 
lymphocytic leukemia 
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 Another risk factor of CLL is the development of Richter syndrome. Richter 
syndrome is the transformation of CLL to an aggressive lymphoma, commonly 
DLBCL or classic Hodgkin lymphoma [4]. Approximately 2-7% of patients with 
CLL develop Richter syndrome more frequently seen in patients with NOTCH1 
mutations or patients who express certain stereotypical immunoglobulin 
molecules [4]. The prognosis of patients with Richter syndrome is generally poor, 
especially for those who are heavily pretreated for CLL and/or who have 
transformation involving lymphocytes that are clonally related to the underlying 
CLL [4]. 
 As seen in table 1.4, there is increasing body of evidence suggesting 
impaired cell-mediated immunity in CLL. These include decreases in T helper 
activity, increases in T suppressor activity, reversal of CD4/CD8 ratio, increased 
expression of interleukin-2 (IL-2) receptors, and defects in large granular 
lymphocytes or natural killer cells [15, 45-48]. Analysis of T cell repertoire of CLL 
patients have shown that oligoclonality is much more common in CD4 and CD8 T 
cells in CLL patients than in age matched controls [49]. It is unclear however; if 
this T cell dysfunction can be reversible in CLL patients. Therefore, it is important 
to understand the molecular mechanisms leading to this immune dysfunction. To 
examine the possible mechanisms of T cell defects in CLL patients, Görgün et al. 
performed a global gene expression analysis of highly purified CD4+ and CD8+ T 
cells from peripheral blood of individuals with CLL compared with age-matched 
healthy donors [50]. Their analysis of the differentially expressed genes 
demonstrated a number of abnormalities in specific pathways. For example, in 
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CD4 cells, Ras-dependent JNK and p38 MAPK pathways were markedly 
changed [50]. These pathways play a major role in the regulation of CD4 T cell 
differentiation into T helper (Th) 1 and Th2 cells. The data demonstrated a 
decrease in the p38 MAPK pathway activator genes, which subsequently can 
impair CD4 differentiation function [50]. Gene expression analysis of CD8 cells 
revealed changes in expression of genes responsible for cytoskeleton formation 
and vesicle trafficking, which leads to decrease in cytotoxicity and effector 
functions of CD8 cells [50]. Moreover, p38 MAPK pathway was also altered in 
CD8+ T cells, which regulates the production of tumor necrosis factor alpha 
(TNF-α), perforin and granzyme [50]. Taken together, these changes in gene 
expression profile of T cells between CLL and normal donors is likely to 
contribute to the failure of T cell responses against tumor cells in CLL. A different 
study demonstrated that CD8 and CD4 T cells from CLL patients have an 
impaired ability to form an immunological synapse with antigen presenting cells 
because of defects in actin polymerization [51]. The formation of immune 
synapse in CD4 T cells allows the directed secretion of IL-2 and other cytokines 
toward the immune synapse and ultimately T cell proliferation [51]. CD8 cytotoxic 
cells form immune synapses that could deliver lethal doses of cytolytic granules 
[51]. Interestingly, a short-term cell contact between CLL cells and healthy 
allogeneic T cells induced the same immunological synapse defects [51]. In a 
follow up study Gribben and colleague found that T cell exhaustion could 
contribute to the T cell dysfunction [52]. T cells from CLL patients had an 
increased expression of exhaustion markers including CD244, CD160, and 
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programmed death-1 (PD1) in comparison to healthy donors [52]. In addition, 
CD8+ cells showed functional defects in proliferation and cytotoxicity caused by 
impaired granzyme packaging and nonpolarized degranulation [52].  
 Furthermore, CLL cells themselves have been reported to produce 
immunosuppressive factors such as transforming growth factor beta (TGF-β) and 
IL-10 [53, 54]. Very few studies have demonstrated the mechanism by which IL-
10 could be playing an immunosuppressive role that leads to CLL disease 
progression. For example, activated CLL cells were shown to inhibit macrophage 
TNF production in co-culture assays in an IL-10-dependent manner, but its 
importance for CLL disease was not tested [55]. In this dissertation we will be 
investigating multiple hypotheses regarding the role of IL-10 in CLL growth and 
disease immunosuppression. 
(1e) Interleukin-10 producing B cells and CLL 
 In addition to their roles as antibody-producing or antigen-presenting cells,  
B lymphocytes are major producers of cytokines such as interleukin-10 (IL-10), 
IL-6, lymphotoxin alpha (LT-α) and TNF-α [56-58]. They have also been reported 
to produce other cytokines such as IL-2, IL-4, interferon gamma (IFN-γ) and IL-
12 [59-61]. The notion that B cells can markedly influence immunity through the 
secretion of cytokines gained momentum when it was observed that B cells could 
differentiate into distinct cytokine-producing subsets termed Be1 and Be2, which 
could subsequently regulate the differentiation of naïve CD4+ T cells into Th1 
cells or Th2 cells, respectively, in vitro [62]. In addition, endogenous B cells were 
found to control immunity through the production of cytokines in vivo in two 
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models of inflammatory diseases, ulcerative colitis (UC) and experimental 
autoimmune encephalomyelitis (EAE) [63, 64]. In both cases, B cells limited 
pathogenic immunity, and improved the disease progression through the 
production of IL-10, a cytokine classically thought to be produced by regulatory T 
cells and some other innate immune cells [63, 64]. Moreover, it has been shown 
that B cells can have similar suppressive functions in humans leading to the 
notion of regulatory B cells (Bregs). For example, B cells from patients with 
relapsing-remitting multiple sclerosis (MS) produce less IL-10 than B cells from 
healthy patients upon stimulation in vitro, which suggests that a defect in this 
suppressive mechanism can induce onset or progression of MS [65]. In other 
studies, B cell depletion therapy resulted in exacerbation of UC in some patients 
who were treated with rituximab (anti-CD20 antibody), wherein the elimination of 
B cells correlated with a loss of IL-10 expression in the intestinal mucosa [66].  
 Regulatory B cells that produce IL-10 are now recognized as an important 
part of the immune system. A subset of B cells producing IL-10 has been recently 
identified and named B10 cells [67]. There are no unique phenotypic markers for 
B10 cells as they share surface markers with previously defined B cells including 
B-1 B cells [67]. They are CD5+CD19hiCD1dhi cells and are defined primarily by 
their competency to produce IL-10 following appropriate stimulation [67]. B10 
cells have been shown to exert a variety of IL-10-dependent regulatory effects 
that are involved in autoimmune disease. Those effects are mediated by multiple 
mechanisms affecting both the innate and adaptive immunity. For example, B10 
cells have been described to negatively regulate the ability of dendritic cells 
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(DCs) to present Antigens [68]. Also, B10 cells suppresse IFN-γ and TNF-α 
responses in vitro and IFN-γ responses in vivo by CD4+ T cells [68, 69]. The 
important regulatory effects of B10 cells have been demonstrated in a variety of 
mouse models of human autoimmune diseases including but not limited to, 
experimental autoimmune encephalomyelitis, inflammatory bowel disease, 
collagen-induced arthritis and systemic lupus erythematosus [68, 70-72]. 
Therefore, it was proposed that we can either improve autoimmune diseases by 
promoting the IL-10 mediated regulatory functions of B cells or we can improve 
antimicrobial or even antitumor immunity by turning down these inhibitory 
processes. 
 As discussed earlier, B-1 cells are thought to be a possible cellular origin 
of CLL cells. One of the interesting features of B-1 cells is their ability to produce 
IL-10 constitutively, which is unlike B10 cells [56, 73]. The production of IL-10 by 
B-1 cells has been shown to act in an autocrine manner and inhibit proliferation 
responses of B-1 cells to toll like receptor (TLR) stimulation by blocking 
degradation of IκBα and translocation of RelA to the nucleus [73]. Interestingly, 
CLL cells have been shown to share this characteristic with B-1 cells in 
constitutively producing IL-10 [54]. However, not much is known about the role of 
IL-10 produced by CLL cells. In this dissertation, we will test a few hypotheses in 
regard to the role of CLL-induced IL-10. 
(1f) Importance of IL-10 in the immune system 
 IL-10 was first described as cytokine synthesis inhibitory factor (CSIF) 
because it was produced by Th2 cells that inhibited Th1 cell activation and 
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cytokine production [74]. Later on IL-10 was shown to exert its anti-inflammatory 
effects by inhibiting antigen presentation by DCs and limiting their secretion of 
proinflammatory cytokines, such as IL-1, IFN-γ and TNF-α [75, 76].  
 IL-10 binds as a homodimer to its receptor, which is a tetramer formed of 
two α (IL-10R1) and two β (IL-10R2) chains [77]. IL-10R1 is the ligand binding 
subunit, while IL-10R2 activates downstream signaling involving Janus tyrosine 
kinases Jak1 and Tyk2 [77]. JAK1 and Tyk2 phosphorylate the cytoplasmic tail of 
IL-10R1, which leads to the recruitment of the signal transducer and activator of 
transcription 3 (STAT3) to the IL-10R [78]. Ultimately, phosphorylated STAT3 
homodimerizes and translocates to the nucleus to promote the expression of IL-
10 responsive genes [78].   
 IL-10 is now known to be produced by multiple types of cells including 
macrophages, DCs, B cells, and various subsets of CD4+ and CD8+ T cells [79]. 
In addition to its role in inhibiting the production of proinflammatory cytokines, IL-
10 is involved in inhibiting the production of various chemokines involved in 
inflammation [80]. Furthermore, IL-10 regulates T cell responses indirectly 
through its effects on macrophages and monocytes, inhibiting their MHC class II 
and costimulatory molecule B7-1/B7-2 expression and limiting their production of 
proinflammatory cytokines and chemokines [79]. IL-10 can also act directly on T 
cells, inhibiting proliferation and production of IL-2, IFN-γ, IL-4, IL-5 and TNF-α 
[81, 82]. Activation of T cells in the presence of IL-10 can induce anergy in T 
cells, which cannot be reversed by IL-2 or stimulation by anti-CD3 and anti-CD28 
[83]. Therefore, IL-10 appears to play an essential role in the regulation of 
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different immune responses. Here we show that IL-10 is also produced by 
chronic lymphocytic leukemia cells. The question here remains as to the role of 
IL-10 in in this leukemic disease sitting. 
(1g) Molecular mechanisms involved in IL-10 production 
 As noted earlier, IL-10 is expressed by various cell types, which account 
for the complexity of its regulation. Many cells of the innate and adaptive immune 
response produce IL-10 and the molecular mechanisms for its regulation differ 
according to the cell type and stimulant, although some common mechanisms 
exist [84]. IL-10 is expressed by macrophages and myeloid DCs, but not by 
plasmacytoid DCs, in response to microbial antigens. The extracellular signal 
regulated kinase 1/2 (ERK1/2) and p38 MAPkinase pathways are two of the main 
signaling pathways activated in these cells resulting in IL-10 expression [84].  
 In macrophages and DCs, the expression of IL-10 can be induced by TLR 
or non-TLR signaling [84]. Activation of TLRs and their adaptor molecules, 
myeloid differentiation primary-response protein 88 (MYD88) and TIR-domain-
containing adaptor protein inducing IFNβ (TRIF), leads to the activation of ERK1 
and ERK2, p38 and nuclear factor-κB (NF-κB) pathways, which in turn result in 
induction of IL-10 expression [84]. In myeloid DCs, non-TLR can signal through 
DC-specific ICAM3-grabbing non-integrin (DC-SIGN) and RAF1, which leads to 
increase in TLR2-induced IL-10 production [84]. Moreover, activation of dectin 1, 
which signals through spleen tyrosine kinase (Syk) and ERK results in IL-10 
production [84]. In macrophages, nucleotide-binding oligomerization domain 2 
(NOD2) signaling downstream of TLR2 has been shown to induce IL-10 
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production [84]. Macrophages from neonatal and aged mice produce more IL-10 
than those from young adults [85]. 
 In T helper cells, molecular mechanisms of IL-10 production have been 
studied to a lesser extent than in macrophages and DCs. Normally, IL-10 
production is accompanied by the expression of the another signature cytokine 
for each subset of Th cells. For example, IL-10 production was first described in 
Th2 cells, where its expression is accompanied by the expression of IL-4, IL-5 
and IL-13 [74]. Indeed IL-10 production in Th2 cells seem to be regulated by the 
same signaling pathways and transcription factors involved in the main Th2 type 
cytokine secretion, which include IL-4, STAT6 and GATA3 [84, 86, 87]. In Th1 
cells, the expression of IL-10 can be induced only under certain conditions [84, 
88]. Strong T cell receptor (TCR) stimulation and endogenous IL-12 have been 
shown to be required for the differentiation of IL-10-producing Th1 cells [89]. 
Moreover, IL-10 expression by Th1 cells is dependent on STAT4 and ERK 
activity [89]. Another T helper cell subset that has been shown to be induce to 
produce IL-10 is the Th17 subset and thus attenuate their pro-inflammatory 
activity [90]. IL-10 expression by Th17 cells appears to occur in a STAT3 and 
STAT1 dependent manner [91]. Furthermore, TGF-β have been shown to induce 
the production of IL-10 by forkhead box P3 (FOXP3)+ T regulatory (TReg) cells in 
vivo and this cytokine can also promote the development of IL-10 producing 
FOXP3- T cells from naïve T cells [92]. 
 Taken together, Th1, Th2 and Th17 cells require the same signals needed 
for their differentiation to produce IL-10. Interestingly, the production of IL-10 by 
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these subsets requires ERK activation, which indicates a common mechanism 
for IL-10 production by T helper cells. But unlike macrophages and DCs, p38 
signaling pathway is not required for the production of IL-10 by T helper cells 
[89]. In addition, it appears that all T cell subsets can produce IL-10; however, 
this depends on the environmental context and the strength of stimulus. For other 
immune cells such as B cells and mast cells, the exact signaling cascades 
leading to IL-10 production remain elusive. A summary of IL-10 expression by 
different immune cells in provided in figure 1.3 [84]. 
 
Figure 1.3: Interleukin-10 production by immune cells 
Saraiva, M. & O'Garra, A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 10, 170-181 
(2010). (Reproduced with permission from Nature). 
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(1h) Transcription factors that regulate IL-10 expression 
 There are many transcription factors that have been described to regulate 
the expression of IL10 in APCs and T helper cells. Figure 1.4 represents both the 
signaling molecules (outer circle) and the transcription factors (inner circle) with a 
validated role in IL10 expression [84]. As relevant to the work presented in this 
dissertation, the transcription factors specific protein 1 (Sp1), Sp3, 
CCAAT/enhancer binding protein-β (C/EBPβ), IFN-regulatory factor 1 (IRF1) and 
STAT3 all have been shown to bind and transactivate IL10 in macrophage and T 
cell lines of mouse and human origin [84]. In addition, in human T cell lymphoma 
cell lines, the NF-κB p50 subunit has been describe to bind the IL10 promoter 
[93]. More importantly, many of these findings are dependent on the cell type and 
the stimulus. For instance, when THP1 cells (a human pro-monocytic cell line) 
were stimulated with LPS, IL10 promoter activity was dependent on an Sp1 site 
located between positions -636 and -631 relative to the initiation site [94]. On the 
other hand, stimulating the same cells with cyclic AMP shows that IL10 promoter 
activity relies on the C/EBP5 motif located between the TATA box and the 
translation start point [95]. Overall, vast number of studies provided evidence that 
IL-10 is not regulated in a simple manner, which is in agreement with its functions 
in regulating various immune responses.  
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(1i) Mechanisms of IL-10 production by normal and malignant B cells 
 As alluded to earlier, in addition to macrophages, DCs and CD4+ T cells, 
other cells of the immune system are also known to express IL-10. Both normal 
and malignant B cells are amongst these cells [54, 55, 73]. It is however not clear 
whether the molecular mechanisms required for the induction of IL-10 by these 
cells are regulated by the same or similar factors that regulate IL-10 production 
by T helper cells, macrophages and DCs. Therefore, the mechanisms involved in 
IL-10 production by normal B cells and CLL cells remain understudied. A recent 
report indicated the importance of B-cell-activating factor of the tumor necrosis 
factor family (BAFF) and its receptor, transmembrane activator and cyclophilin 
ligand interactor (TACI), for IL-10 production by normal and leukemic B cells [96]. 
Figure 1.4: Transcription factors involved in IL-10 production 
Saraiva, M. & O'Garra, A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 10, 170-181 
(2010). (Reproduced with permission from Nature). 
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Stimulation of both human and mouse CLL cells with BAFF led to an increase in 
IL-10 production [96]. In addition, splenic cells from TACI-deficient mice were 
unable to secrete IL-10 following TLR stimulation [96]. Another study attempted 
to define the molecular mechanisms involved in the variation in levels of IL-10 
produced by human CLL cells. Their data suggested an epigenetic control of IL-
10 production, in which differential IL-10 gene methylation was responsible for 
the variability of IL-10 production by human CLL cells [97]. In addition, they found 
that IL-10 induction by CpG stimulation requires STAT3 activity [97].  
 Due to the importance of tonic B cell receptor signaling in the survival of 
normal B cells, as well as its impact on the survival and growth of malignant B-
cell clones in CLL and in other non-Hodgkins lymphomas, here we investigated 
the role of BCR signaling in IL-10 production by CLL cells [98-101]. We 
discovered a novel role of BCR signaling in IL-10 production by CLL cells [54]. 
Our studies described in the thesis showed that BCR dependent constitutive 
activation of Src or Syk family kinase is required for constitutive IL-10 production 
by both mouse and human CLL cells. The studies to understand the molecular 
pathways leading to IL-10 production CLL cells by BCR signaling could provide 
valuable information on possible targets for IL-10 manipulation and the 
modulating of the immune response in CLL. 
(1j) Chronic lymphocytic leukemia study models  
  Expression of T-cell leukemia oncogene 1 (TCL1) has been described as 
a molecular marker of aggressive disease and poor outcome in patients with CLL 
[9]. In 1994, Giandomenico Russo and colleagues were studying the TCL1 locus 
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on human chromosome 14q32.1 that was found to be commonly involved in 
chromosomal translocations and inversions with one of the TCR loci in human T 
cell leukemias and lymphomas [102]. They eventually discovered a gene coding 
for a 1.3 kb transcript, which is expressed only in a restricted subset of cells 
within the lymphoid lineage while expressed at high levels in leukemic cells with 
specific translocations or inversions within the chromosome regions 14q11 and 
14q32 [102]. This gene is known as the TCL1 gene, which is preferentially 
expressed early in T and B cell differentiation [102]. TCL1 has been described as 
a novel Akt kinase coactivator, which facilitates the oligomerization and activation 
of Akt in vivo, promoting Akt-dependent cell survival [103]. To study the role of 
TCL1 in the generation of T cell malignant transformation, a transgenic mouse 
model that expresses the human TCL1 gene under the transcriptional control of 
the T cell specific gene promoter p65lck was generated [104]. The lck-TCL1 
transgenic mice developed mature T cell leukemias at old age (15-20 months), 
while younger mice presented with pre-leukemic T cell expansions 
expressing TCL1 [104]. After the demonstration that TCL1 overexpression 
causes mature T cell proliferation in transgenic mice, many studies revealed 
strong expression of the gene in almost all tumor cells of B cell lineage, which 
indicated a possible role for TCL1 in B cell proliferation [105]. For example, 
TCL1 was found to be expressed in lymphoblastic lymphoma, chronic 
lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, Burkitt’s 
lymphoma, diffuse large B cell lymphoma, and primary cutaneous B cell 
lymphoma [106]. Following these studies, a new mouse model 
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with TCL1 expressed at similar levels in both B and T cells was generated [107]. 
These transgenic mice developed Burkitt-like lymphoma and diffuse large B cell 
lymphoma beginning 4 months of age and only one mouse developed a T cell 
malignancy at 15 months, which is consistent with a longer latency for 
transformation of T cells by TCL1 [107]. Finally, to elucidate the role of TCL1 in B 
cell development and B cell malignancies, Bichi et al. generated the Eµ-TCL1 
transgenic mice that overexpress the human oncogene TCL1 under the control of 
the B-cell-specific μ enhancer and the IGVH promoter to target gene expression 
specifically to B cells (Figure 2.1) [108]. Starting at 2 months of age, CD5+ B cells 
were detected in the peritoneal cavity of Eμ-TCL1 mice, which became evident in 
the spleen by 3-5 months and in the bone marrow by 5-8 months [108]. At 13-18 
months of age, the Eμ-TCL1 mice display an overt disease with an expansion of 
CD5+CD19+ B cell population in both lymphoid and non-lymphoid organs, 
associated with splenomegaly, hepatomegaly and lymphadenopathy, 
recapitulating the main features of human CLL [108]. The Eμ-TCL1 transgenic 
mouse became the first of a number of engineered mice to develop a CLL-like 
disease but one of the very few to closely resemble the real human disease 
[109]. 
 Several other mouse models mimicking genetic lesions found in CLL 
(13q14 deletion), transgenic for genes that are overexpressed in the disease 
(including APRIL, BCL2 X traf2dn, ROR1), or driven by ectopic oncogene 
expression (IgH.T and IgH.TEμ) have been generated to model CLL [109]. In all 
of these mouse models including the Eμ-TCL1 mouse, the disease develops late 
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in life and resembles the indolent disease course of CLL. In addition, 
transformation to CLL appears to be driven by the expansion of peritoneal B-1a 
cell, as suggested by the expression of CD5 and of unmutated IGHV genes, high 
levels of IgM, and low levels of IgD and CD23 [109]. However, the most notable 
difference among these CLL mouse models and the Eμ-TCL1 mouse is the 
penetrance of the phenotype. The penetrance is highest in the Eμ-TCL1 mice, 
intermediate in the 13q14-MDR and the APRIL transgenic mice and lowest in the 
ROR1 transgenic mice (5%) [109].  
 In this dissertation, we utilized the Eμ-TCL1 mouse model for our studies 
due to the close resemblance to human CLL disease and the high penetrance of 
the disease. CLL cells in mice also respond to various types of therapeutic 
regimens effective for human CLL (e.g., fludarabine, ibrutinib, etc.). More 
importantly, T cell dysregulation such as decrease in T cell activation and 
increase in regulatory T cell numbers are characteristics of both Eμ-TCL1 mice 
and human CLL patients [110]. CLL development in these transgenic mice is 
associated with similar impairment of T cell function and alteration of gene 
expression in CD4 and CD8 T cells to that observed in human patients with CLL 
[111]. T cell dysfunction in Eμ-TCL1 mice and in CLL patients has been shown to 
contribute to the immunosuppression status that is associated with disease 
progression and susceptibility to infections, which are the leading causes of 
death in CLL patients [13, 111-113]. Finally, it is worth noting that in our Eμ-TCL1 
mice cohort, mice develop a full CLL-like disease at 10-15 months of age. The 
similarities with human CLL validate the use of Eμ-TCL1 mice as a model for 
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further analyses of ways to prevent and reverse cancer-induced immune 
dysfunction. 
(1k) Study aims 
As discussed above, chronic lymphocytic leukemia disease is associated 
with an immunosuppression status, which is the leading cause of death in CLL 
patients [13-15]. Many mechanisms of immunosuppression have been 
investigated in CLL. CLL cells themselves secrete an immunosuppressive factor, 
IL-10. In this study, we utilized the Eμ-TCL1 mouse model as well as primary 
human CLL cells and the human CLL cell line MEC-1 to investigate the role of IL-
10 in both survival and immune responses in CLL by addressing the following 
specific aims: 
1. IL-10 regulates the proliferation responses to normal B-1 cells, which are 
thought to be the cellular origin of CLL. Similar to normal B-1 cells, Eμ-
TCL1 CLL cells also produce IL-10 constitutively. Here we will test the 
hypothesis that IL-10 may regulate the survival and proliferation of CLL 
cells. 
2. Since IL-10 in a well-known immunosuppressive cytokine, we will test the 
hypothesis that CLL-derived IL-10 may have role in suppression of host 
anti-CLL immune response. 
3. The mechanism of IL-10 production by B cells is understudied. We will 
investigate these possible mechanisms of IL-10 production by CLL cells 
with the aim of identifying therapeutic targets. 
Copyright © Sara Samir Alhakeem 2017 
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CHAPTER 2 
Materials and Methods 
(2a) Mice and cells 
 C57BL/6J, B6.129S2-Il10rbtm1Agt/J (IL-10R-/-), and NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were obtained from The Jackson Laboratory 
(Bar Harbor, ME). NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mice were obtained 
from Taconic (Hudson, NY). Eμ-TCL1 mice in BL/6 background were provided by 
Dr. John Byrd (Ohio State University, OH) and bred in house. Mice were housed 
under specific pathogen free conditions in micro-isolator cages under the 
Institutional Animal Care and Use Committee (IACUC) approved protocol. The 
University of Kentucky IACUC protocol number for this study is 2011-0904. The 
described studies are approved under this protocol. Cohorts of Eµ-TCL1 mice 
were maintained and monitored regularly for CLL cells in blood by flow 
cytometry. Mice were bled by submandibular bleeding using a lancet [114]. Blood 
was collected in K2 EDTA Microtainer tubes (BD #365974, San Diego, CA). Most 
Eµ-TCL1 mice developed CLL between 6-9 months of age (at least 30% 
CD5+CD19+ B cells in the blood). Mice were euthanized when CLL cells were 80-
90% or when their body condition score (BCS) was ≤2. BC scoring technique is 
as followed: with BCS=5 the mouse is smooth and bulky, bone structure 
disappears under flesh and subcutaneous fat; BCS=4 the mouse spine is a 
continuous column and vertebrae palpable only with firm pressure; BCS=3 the 
mouse vertebrae and dorsal pelvis is not prominent but palpable with slight 
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pressure; BCS=2 the mouse segmentation of vertebral column is evident and the 
dorsal pelvic bones are readily palpable; BCS=1 the mouse skeletal structure 
extremely prominent with little or no flesh cover and the vertebrae is distinctly 
segmented [115]. In addition to using CLL cells from primary Eμ-TCL1 mice, we 
adoptively transfer CLL cells from spleens of euthanized Eµ-TCL1 mice with 80-
90% CLL into syngeneic mice, which lead to a reliable and consistent 
development of the disease in the recipient mice within weeks of injection and 
splenomegaly (Figure 2.1). Adoptive transfer of Eμ-TCL1 cells consisted of 
transferring 1-10x106 Eμ-TCL1 splenic cells into C57BL/6J mice via retro-orbital 
injection. 
 For in vitro experiments, Eμ-TCL1 CLL cells were cultured in RPMI 1640 
medium (Corning #10-040-CV, New York, NY) supplemented with 10% Fetal 
Bovine Serum (FBS) (Atlanta Biological Systems, Flowery Branch, GA). The 
human CLL cell line, MEC1, was obtained from Dr. Natarajan Muthusamy at 
Ohio State University. MEC1 cells were cultured in Iscove's Modified Dulbecco's 
Medium (IMDM) (ThermoFisher Scientific #12440061, Waltham, MA) 
supplemented with 10% FBS. 
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(2b) Patients 
 Patients with CLL were recruited from the University of Kentucky Markey 
Cancer Center. All 18 patients gave informed consent according to protocols 
approved by the University of Kentucky Institutional Review Boards. Blood CLL 
cells were purified using Ficoll-Paque PLUS density gradients (GE HealthCare 
#17-1440-02, Pittsburgh, PA). CLL preparations were always >90% CD5+CD19+ 
B cells. For healthy controls, Leukopak units were obtained from the Kentucky 
blood bank. B cells were enriched using Ficoll-Paque PLUS density gradients 
and human CD19+ Microbeads (Miltenyi Biotech #130-050-301, San Diego, CA). 
For in vitro studies, human CLL cells were cultured in RPMI 1640 medium 
supplemented with 10% FBS. 
Spontaneous Model 
10-15 Months of age 
Primary Eµ-TCL1 Spleen 
CD5 
 
C
D
19
 
86.61% 
Adoptive Transfer Model 
Inject 104-107 cells IV 
no irradiation required 
Syngeneic model 
3-8 weeks post injection 
Adoptive Transfer spleen 
CD5 
C
D
19
 
92% 
β-globin 
Figure 2.1: Production of Eμ-TCL1 transgenic mice and the adoptive transfer model. 
Gene organization for the transgene was adapted from Bichi, R. et al. Human chronic lymphocytic leukemia modeled in 
mouse by targeted TCL1 expression. Proceedings of the National Academy of Sciences of the United States of America 
99, 6955-6960 (2002). Copyright © 2002, The National Academy of Sciences 
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(2c) Reagent 
 PMA (P1585), Ionomycin (407952), LPS (L2018), Thiazolyl Blue 
Tetrazolium Bromide (MTT) (M5655), and monoclonal anti-β-actin antibody 
(A5441) were from (Millipore Sigma-Aldrich, St. Louis, MO). Purified anti-mouse 
IL-10 (554463) and IL-10R (550012) antibodies were obtained from (BD 
PharMingen, San Diego, CA). AffiniPure F(ab')2 Fragment Goat anti-Mouse IgM 
(115-006-020) and AffiniPure F(ab')2 Fragment Goat anti-human IgM (109-006-
129) antibodies were purchased from (Jackson ImmunoResearch Laboratories, 
West Grove, PA). Mouse anti-CD19 MicroBeads (130-052-201), anti-CD8a 
MicroBeads (130-049-401) and CD4+ T cell isolation kits were purchased from 
Miltenyi Biotech. Dasatinib (0003-0528-11) was manufactured by (Bristol-Myers 
Squibb Company, Seattle, WA). Syk inhibitor IV (Bay 61-3606) (57-471-42MG) 
was obtained from (EMD Millipore Calbiochem, Billerica, MA). Mithramycin A 
(BML-GR305-0001) was purchased from (Enzo Life Sciences, Farmingdale, NY). 
Ibrutinib (A3001) and ERK1/2 inhibitor (A3805) were obtained from (APExBIO, 
Houston, TX). Phosphate buffered saline (PBS) (#SH30256.FS) was obtained 
from GE HealthCare. Carboxyfluorescein succinimidyl ester (CFSE) (C1157) was 
purchased from ThermoFisher Scientific. Mouse fluor-conjugated anti-CD5 
(100606 or 100608), anti-CD19 (115520 or 115508 or 115512), anti-CD45 
(103114 or 103110), anti-CD11b (101212), anti-CD4 (100412 or 100510), anti-
CD8 (100706 or 100708), anti-IL-10R (112706), anti-IFN-γ (505806), and anti-IL-
10 (505010) as well as human anti-CD5 (364022), anti-CD19 (302208) and anti-
CD45 (368512) antibodies, fixation buffer (420801) and intracellular staining 
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permeabilization wash buffer (421002) were all acquired from (BioLegend, San 
Diego, CA). Mouse Anti-CD90.2 (Thy1.2) (553013) was purchased from BD 
PharMingen. Antibodies to P-Syk (2711), total Syk (2712), P-p38 (9211), total 
p38 (9212), P-ERK1/2 (9101), P-STAT3 (9145), total STAT3 (4904) and GAPDH 
(2118) were obtained from (Cell Signaling Technology, Danvers, 
Massachusetts). Antibodies to IL-10 (SC-365858), Sp1 (SC-17824), Lyn (SC-15), 
and total ERK1 (SC-94) were acquired from (Santa Cruz Biotechnology, Santa 
Cruz, CA). Peroxidase coupled goat anti-rabbit (SC-2004) and anti-mouse (SC-
2005) Ig secondary antibodies were also acquired from Santa Cruz 
Biotechnology. Mouse IL-10 (5261) and SimpleChIP kit (9003) were purchased 
from Cell Signaling Technology.  
(2d) Immunofluoresence analysis and cell sorting 
 Single-cell lymphocyte suspensions from mouse tissues were prepared as 
described before. Spleens were pressed through a 40μm strainer using the 
plunger end of a syringe in Hank’s buffered salt solution (HBSS) (Millipore 
Sigma-Aldrich #H6136-10XL). Tibiae and femora were harvested from mice. The 
bones were flushed with a 26G syringe in HBSS to obtain bone marrow single 
cell suspension. Peritoneal cells were obtained by peritoneal lavage with ~30mL 
of HBSS. Mouse blood mononuclear cells were isolated by centrifugation after 
subjecting 100-200μl of blood to RBCs lysis. Cells were resuspended in RPMI 
1640 medium supplemented with 10% FBS. For multi-color immunofluorescence 
analysis, single-cell suspensions of mononuclear cells (106 cells) were incubated 
with normal rat IgG (10μg/106 cells) at 4°C for 15 min to block Fcγ receptors. The 
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cells were then labeled with fluorochrome-conjugated anti-mouse antibodies for 
30 minutes on ice. Cells were washed with staining buffer (2% FBS in 1xPBS). 
Cells with the forward and side light scatter properties of single viable 
lymphocytes were analyzed using Becton Dickinson (San Jose, CA) LSRII flow 
cytometer and CellQuest Pro software. Anti-CD19, anti-CD11b and anti-CD5 
were used to identify and sort B-1a (CD19+ CD5+ CD11b+), B-1b (CD19+ CD5- 
CD11b+), B-2 (CD19+ CD5- CD11b-) cells from the peritoneum of C57BL/6J 
mice using iCyt Synergy sorter system from Sony Biotechnology (San Jose, CA). 
CD45 staining was used to gate on lymphocytes and myeloid cells. Anti-CD19 
and anti-CD90.2 antibodies were used to identify and sort T cells (CD19- 
CD90.2+) for the adoptive transfer experiments also using the iCyt Synergy 
sorter. Intracellular staining was performed according to Biolegend protocol. 
Briefly, cells were stimulated with PMA (20ng/ml) and Ionomycin (1μg/ml) for 4 
hours in RPMI media supplemented with 10%FBS at 37°C. After surface 
staining, cells were fixed with 1X PBS solution containing 4% paraformaldehyde 
for 20 minutes at room temperature, permeabilized using BioLegend Intracellular 
Staining Permeabilization Wash Buffer, and finally stained with the antibody of 
interest for 30 minutes on ice. 
(2e) Enzyme-linked immunosorbent assay (ELISA)  
 For cytokine analysis, normal B-1, murine CLL and human CLL cells were 
cultured in triplicate (2x106 cells/mL) for 24 hours in 96-well plate with various 
stimulants or treatments. Cells were removed by centrifugation and supernatants 
were assayed immediately or stored at -80°C. Plasma from mice was obtained 
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by centrifuging blood collected in EDTA tubes at the time of euthanization by 
cardiac puncture and the samples were stored at -80°C. IL-10 levels in 
supernatants or plasma were quantified using IL-10 OptEIA ELISA kit (BD 
#555252). IFN-γ levels were measured using IFN-γ OptEIA ELISA kit (BD# 
555138). Human plasma or secreted IL-10 levels were quantified using IL-10 
ELISA MAX set (BioLegend #430601). 
(2f) In vitro cell survival and proliferation assays 
 CLL cell survival was determined by MTT assay [116]. Splenic CLL cells 
were stimulated with 5μg/ml LPS in the presence or absence of anti-IL-10R 
(10μg/ml) or anti-IL-10 (10μg/ml) antibodies. After 48 hours, media was changed 
and cultured with MTT for 4 hours followed by solubilization in acidic isopropanol 
and spectrophotometric measurements at 560nm and 690nm. To calculate final 
optical density (OD) counts, measurements at 690nm are subtracted from 560nm 
measurements to account for background readings.  
 For T cell proliferation and differentiation studies, CD8+ cells were purified 
using anti-CD8+ Microbeads using the autoMACS cell separator (Miltenyi 
Biotec). Cells then were and cultured (1-2 x 105 cells) with irradiated mouse CLL 
cells (25Gy) (2 x 105 cells) for 72 hours. Irradiation was performed in a Mark I-68 
Cesium γ-irradiator (J.L Shepherd and Associates) on a rotating platform. The 
cultures were pulsed with 1.0 μCi of 3[H] thymidine for 4 hours. The incorporated 
radioactivity was measured after harvesting cells onto a 96-well-plate by using a 
Matrix 96 β-counter (Packard, Downers Grove, IL). For IFN-γ analysis, 
supernatants were collected after 24 hours. All cell cultures were set in triplicates 
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in 96-well-plate at cell density of 2x106cell/mL. 
(2g) Immunoblotting 
 CLL cells (mouse or human) were cultured at 5x106 cells/well in a 6 well 
plate for treatments indicated in figures. At each time point, cells were collected 
and washed twice using HBSS. Cells were then lysed in Cell Signaling lysis 
buffer (#9803) containing 1mM PMSF (Sigma #P7626), 2mM NaF (Sigma #S-
1504), 2mM Na3VO4 (Sigma #S-6508) and 1x protease inhibitor cocktail (Roche 
#5892953001) (Indianapolis, IN) for 15 minutes on ice and collected by 
centrifuging at highest speed setting. Protein concentration in cell lysates was 
estimated by the Bicinchoninic Acid (BCA) assay kit (Thermo Scientific #23227). 
Protein lysates were diluted in 4x sodium dodecyl sulfate (SDS) sample buffer 
(100mM Tris-HCl, pH 6.8, 30% glycerol, 4% SDS, 5% 2-ME and 0.01% W/V 
bromophenol blue) to a 1x final concentration and boiled for 10 min. The BIO-
RAD Mini PROTEAN Tetra System was used for both gel electrophoresis and 
transfer. 30μg total protein/sample of total lysate was subjected to sodium 
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis. 7µl of Precision Plus 
Protein dual color ladder (BIO-RAD #1610394, Hercules, CA) with a size range 
spanning 10-250 kDa was used as a size standard for every gel. 10% or 12% 
polyacrylamide gels were run with running buffer (25mM Tris, 192mM glycine, 
0.1% SDS, pH 8.3) at 100Volts and ~150mA for 10 min to stack the proteins, and 
later at 150Volts and ~150mA for 1 h to separate the proteins. Separated 
proteins were transferred to polyvinylidene difluoride membranes (EMD Millipore 
#IPVH00010) with transfer buffer (25mM Tris, 192mM glycine, 20% methanol, pH 
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8.3). Transfer was performed at 100V and ~150mA for 1.5 h at 4°C. Membranes 
were blocked at room temperature for 1hr with 5% milk or 3% bovine serum 
albumin (when probing for phosphorylated proteins) in 1x TBST that was diluted 
from 10x TBST (0.5M Tris, 1.5M NaCl and 1% Tween-20). The membranes were 
then probed with appropriate primary antibodies at 4°C overnight, followed by 
horseradish peroxidase-conjugated secondary antibodies at room temperature 
for 1hr. The blots were developed with HyGLO chemiluminescence reagent 
(Denville Scientific #E2400, Holliston, MA) and exposed to HyBlot CL 
autoradiography film (Denville Scientific #E3012). Band densitometry analysis 
was performed using the NIH ImageJ program. Protein expression was 
normalized to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), β-actin or 
total target protein expression as appropriate. 
(2h) CLL and T cell adoptive transfer and CFSE Labeling 
 Adoptive transfers were performed by transferring 1-10x106 Eμ-TCL1 
splenic cells into C57BL/6J or IL-10R KO or NSG mice (without any 
preconditioning) intravenously via retro-orbital injection. CLL disease was 
monitored by periodic submandibular bleeding and CD5+CD19+ cells were 
quantified by flow cytometry [117]. For CFSE Labeling, CLL cells were 
resuspended at 107 cells/ml in 1xPBS + 10mM CFSE, incubated at 37°C for 20 
min, and then washed with 1xPBS to prepare for retro-orbital injection [118]. 
 For total T cell adoptive transfer experiments, C57BL/6J and IL-10R KO 
mice were injected with 4 x 106 CLL cells for priming. 14-17 days after injection, 
splenic T cells were sorted using anti-CD90.2 antibody. 4 x 106 T-depleted CLL 
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cells along with sorted 0.5 x 106 T cells (NSG) or 0.25 x 106 T cells (NOG) were 
adoptively transferred and disease was monitored weekly by bleeding. For CD8+ 
T cell adoptive transfer, C57BL/6J and IL-10R KO mice were injected with 4 x 106 
CLL cells for priming. 14 days after injection, splenic CD8+ T cells were isolated 
using CD8+ microbeads and the autoMACS cell separator. 4 x 106 T-depleted 
CLL cells along with sorted 0.125 x 106 T cells (NSG) were adoptively transferred 
and disease was monitored weekly by bleeding. 
(2i) Quantitative Real-Time PCR (qRT-PCR) 
 Total RNA was isolated from Eμ-TCL1 CLL cells using TRI reagent 
(Sigma-Aldrich #T9424). RNA was quantified and 2μg of total RNA was 
subsequently used to make cDNA using qScript cDNA SuperMix (Quanta 
Biosceince #95048-100, Gaithersburg, MD) according to the manufacturer’s 
protocol. iTaq Universal SYBR Green Supermix (BIO-RAD #172-5121) was used 
to carryout the qRT-PCR reaction. qRT-PCR was performed and analyzed 
(comparative CT (ΔΔCT) method) on StepOnePlus Real-Time PCR System from 
(Applied Biosystems, Foster City, CA). Primer sequences used are described in 
Table 2.1. The 18s-specific primers were used for loading control. All primers 
were obtained from (IDT technologies, Coralville, IA). 
Table 2.1: List of qRT-PCR Primers 
Primer Sequence Manufacturer 
IL-10 Forward 5’-ACTGGCATGAGGATCAGCAG-3’ IDT technologies 
IL-10 Reverse 5’-AGAAATCGATGACAGCGCCT-3’ IDT technologies 
SP1 Forward 5’-TGCCACCATGAGCGACCAAGATCA-3’ IDT technologies 
SP1 Reverse 5’-TGCTGCTGCTTCGAGTCTGAGAAA-3’ IDT technologies 
18S Forward 5’- CGCCGCTAGAGGTGAAATTCT -3’ IDT technologies 
18S Reverse 5’-CGAACCTCCGACTTTCGTTCT-3’ IDT technologies 
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(2j) Short hairpin RNA (shRNA) sequence and cell infection 
 Lyn shRNAs in the pLKO.1 lentiviral vector were validated and selected by 
the RNAi Consortium and glycerol stocks were purchased from ThermoFisher 
Scientific (#RHS4533). MEC1 cells were seeded at a density of 1.5 x 106 cells/ml 
in a 6-well assay plate, infected with 25-50μl of concentrated shRNA lentiviral 
supernatants with the addition of polybrene (10μg/ml) and centrifuging for 90 
minutes at 2800rpm and 10°C. Virus and cells were incubated for 24hrs at 37°C 
and then fresh media was replenished. Puromycin antibiotic selection began at 
day 3 and remained in culture for entire period of experimentation after proper 
titration. All lentiviral infections were assayed by Western blot analysis with anti-
Lyn antibody. Lyn shRNA Clone# TRCN0000010101 is represented in this paper. 
(2k) Chromatin Immunoprecipitation (ChIP) for qChIP analysis 
 ChIP analysis was performed using Cell Signaling SimpleChIP Enzymatic 
Chromatin IP kit following manufacturer’s protocol. The proteins and DNA were 
cross-linked with 1% formaldehyde, lysed, and the DNA was sheared into 150-
900 bp fragments. Proteins linked to the DNA were immunoprecipitated with anti-
Sp1 antibody (using rabbit IgG antibody as control). Subsequently, immune 
complexes were eluted from the beads, protein-DNA crosslinks were reversed, 
and DNA was isolated after phenol/ chloroform/isoamyl alcohol extraction 
followed by ethanol precipitation. For qChIP, RT-PCR was performed on the 
eluted DNA using SYBR Green Reaction Mix as described in (section 2i). The 
primers used to amplify specific regions of the IL-10 promoter described to 
contain Sp1 binding site [119] were as follows; forward, 5’- 
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GCAGAAGTTCATTCCGACCA-3’; reverse, 5’-GGCTCCTCCTCCCTCTTCTA-3’. 
For calculating fold changes, we used the fold enrichment method. This 
normalization method is also called 'signal over background' or 'relative to the no-
antibody control'. With this method, the ChIP signals are divided by the no-
antibody signals, representing the ChIP signal as the fold-increase in signal 
relative to the background signal. The assumption of this method is that the level 
of background signal is reproducible between different primer sets, samples, and 
replicate experiments. 
(2l) Tissue Histology and Disease Scoring  
Colons were dissected from euthanized mice and fixed in 10%-buffered formalin 
(Fisher Scientific #SF93-4, Fair Lawn, NJ), embedded in paraffin, and stained 
with hematoxylin and eosin (H&E) by the University of Kentucky histology 
services. Histological scoring was based on the method described previously by 
Berg et al. [120]. Briefly, a score from 0 to 4 was based on criteria summarized in 
table 2.2 [120]. 
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(2m) Statistical analysis 
GraphPad Prism 7 was used for statistical analyses (GraphPad Software, Inc., 
La Jolla, CA). Statistical significance of differences between groups was 
evaluated by Student’s t test or Tukey’s multiple comparisons test as appropriate 
and p values < 0.05 were considered significant. 
 
 
 
 
Copyright © Sara Samir Alhakeem 2017 
Grade Criteria 
0 No change from normal tissue. 
1 
Few multi-focal mononuclear cell infiltrates in the lamina propria. 
Minimal epithelial hyperplasia. 
Slight to no depletion of mucus from goblet cells. 
2 
Several multifocal, mild inflammatory cell infiltrates in the lamina propria 
composed primarily of mononuclear cells with a few neutrophils. 
Mild epithelial hyperplasia and mucin depletion. 
Occasional small epithelial erosions. 
Inflammation rarely involving the submucosa. 
3 
Lesions involved a large area of the mucosa. 
Moderate inflammation often involving the submucosa but rarely 
transmural. Inflammatory cells are a mixture of mononuclear cells as 
well as neutrophils. 
Crypt abscesses are present. 
Moderate epithelial hyperplasia and mucin depletion. 
Occasionally observed ulcers. 
4 
Lesions involved most of the intestinal section. 
Severe Inflammation, including mononuclear cells and neutrophils, and 
was sometimes transmural. 
Epithelial hyperplasia marked with crowding of epithelial cells in 
elongated glands. 
Few mucin containing cells. 
Crypt abscesses and ulcers are present. 
Table 2.2: Criteria for histological scoring of the colon 
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CHAPTER 3 
Chronic lymphocytic leukemia cells produce IL-10 constitutively, which 
does not affect their survival in vitro 
 
 Peritoneal B-1 cells were shown early on to have the ability to produce 
Interleukin-10 constitutively [56]. In a recent study, a human CD11b+ B-1 cell 
subset was also found to constitutively secrete IL-10 [121]. This constitutive 
nature of IL-10 production by B-1 cells differs from the newly described B10 
subset, which can produce IL-10 but requires further activation in order to do so, 
such as anti-CD40, CPG and LPS stimulation [122, 123]. As described earlier, B-
1 cells are further subdivided into B-1a and B-1b based on the differences in CD5 
expression [29]. Among the different subsets of peritoneal B-1 cells, B-1a cells 
produced the highest amount of IL-10 constitutively, followed by B-1b cells [73]. 
Splenic B-1a cells produced much less IL-10 than peritoneal B-1a cells but more 
than splenic B-2 cells [73]. We previously demonstrated that IL-10 has 
autoregulatory effects in peritoneal B-1 cells through an inhibitory feedback 
mechanism, which affects their proliferation response to stimulation with LPS 
[73]. This autoregulation was found in response to TLR4 as well as ligation of 
TLR2, TLR3, TLR7, and TLR9 receptors [73]. Splenic B-1 cells did not exhibit 
this autoregulation, as their TLR responses were not enhanced by anti–IL-10R 
antibodies [73]. The autoregulatory effect extends to the differentiation response 
of B-1 cells. The autoregulation was found to be a result of inhibition of the 
classical NF-κB signaling by IL-10 [73]. In a recent study, the well-known 
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hyporesponsiveness of B-1 cells to BCR signaling was also found to be a result 
of the feedback-inhibitory effects of B-1 cell–derived IL-10 [54]. As described 
earlier, B-1 B cells are thought to be a possible cell of origin for murine CLL cells. 
Normal B-1 B cells and the Eμ-TCL1 CLL cells share many characteristics. 
Preliminary studies showed that Eμ-TCL1 CLL cells constitutively produce IL-10 
[54]. Since IL-10 has autoregulatory effects in B-1 cells, we hypothesized that IL-
10 could be playing a similar role in Eμ-TCL1 CLL cells as they are also known to 
be hyporeactive to BCR and TLR ligation. Therefore, in this chapter we further 
characterized the production of IL-10 by Eμ-TCL1 CLL cells and tested if the 
constitutively produced IL-10 plays a role in the survival and proliferation of Eμ-
TCL1 CLL cells in vitro. 
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Results 
(3a) Constitutive IL-10 production by Eμ-TCL1 CLL cells  
 Eμ-TCL1 CLL cells (or simply CLL cells) are defined by the co-expression 
of the surface molecules CD5 and CD19. For the studies performed here we use 
splenic cells from the primary Eμ-TCL1 mouse as well as splenic cells from the 
CLL adoptive transfer mice described in the methods. Figure 3.1A shows a 
representative flow cytometry dot plot of spleen cells from both a normal 
C57BL/6 mouse (top) and an adoptively transferred mouse with CLL (bottom) 
stained with anti-CD5 and anti-CD19 antibodies. The majority of the splenic cells 
from the adoptively transfer mouse are CLL cells and are defined by ≥80% 
CD5+CD19+ cells, while normal C57BL/6 mouse spleen would only have <10% of 
CD5+CD19+ cells (normal B-1 cells). TCL1 expression can also be used to 
distinguish between normal B-1 cells and CLL cells as shown in Figure 3.1B.  
 Since CLL cells obtained from each Eµ-TCL1 mouse are unique (based 
on VH gene expression), we first tested if all Eµ-TCL1 CLL cells produced IL-10 
constitutively. Cells from spleens of Eμ-TCL1 mice share a similar functional 
phenotype with peritoneal CD5+CD19+CD11b+ B-1a cells in that they both 
secrete IL-10 constitutively, although this constitutive production is small in CLL 
from some Eµ-TCL1 mice with CLL (Figure 3.2A). Here we confirmed that this 
constitutive production is a property of CLL cells themselves by purifying CLL 
cells using CD19+ microBeads from spleens of Eμ-TCL1 mice. Purified CD19+ 
CLL cells produced a significant amount of IL-10 after 24 hours in culture, which 
was comparable to the unpurified splenic cells of Eμ-TCL1 de novo and adoptive 
transfer models (Figure 3.2A). Since the majority of normal B-1 cells are derived 
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from the peritoneal cavity, we also tested CLL cells derived from the peritoneal 
cavity for their ability to secrete IL-10. We found that peritoneal CLL cells also 
secrete IL-10 constitutively (Figure 3.2A). Finally, we demonstrated that LPS 
enhances IL-10 production by B-CLL cells, another property shared with normal 
B-1 cells (Figure 3.2B). In addition, even the CLL cells that produce low levels of 
IL-10 constitutively produce high levels of IL-10 upon LPS stimulation. 
(3b) Neutralization of IL-I0 or blocking with anti-IL-10R antibody does not affect 
the survival of the Eμ-TCL1 CLL cells  
 While it is known that B-CLL cells produce IL-10, very few studies address 
the direct effects of CLL-induced IL-10 on CLL cells growth and survival. We 
have previously reported that IL-10 produced by normal B-1 cells regulated their 
proliferation responses to TLR stimulation as well as to BCR ligation [54, 73]. 
However, neutralization of CLL-derived IL-10 using anti-IL-10 antibodies or anti-
IL-10R antibodies did not affect the survival of the CLL cells as shown by MTT 
assay (Figure 3.3A) or their proliferation responses shown by Thymidine uptake 
experiments (Figure 3.3B). LPS stimulation enhanced CLL survival but only had 
a modest effect on their proliferation. Neutralization of IL-10 did not affect the 
LPS induced increases in survival or proliferation. Thus, the CLL cells appear to 
be distinct from normal B-1 cells in not responding to IL-10-mediated suppressive 
affects in vitro. This lack of response to blocking IL-10 signal may be due to 
absence of IL-10R on CLL cells and therefore inability to signal. Hence, we 
measured the levels of IL-10R on the surface of CLL cells and the functional 
ability of the receptor to induce downstream signaling. Flow cytometry analysis of 
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IL-10R on the surface of CLL cells derived from Eμ-TCL1 mice confirmed the 
presence of IL-10R on CLL cell surface (Figure 3.3C). Then to confirm the 
functionality of the IL-10R, we tested if exogenous IL-10 would induce the well-
known downstream signaling by inducing phosphorylation of STAT3 transcription 
factor. Indeed, treatment of CLL cells with exogenous IL-10 induced 
phosphorylation of STAT3 in comparison to untreated cells (Figure 3.3D). Thus 
IL-10 receptor appears to be functional in CLL cells. 
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Figure 3.1: Flow cytometry and western blot representation of CLL cells 
A) C57BL/6 mice injected IV with either PBS (top) or 4x106 CLL cells (Bottom). 
After 4 weeks, both splenocytes from recipient mice were stained with CD5 mAb 
and CD19 mAbs. Representative dot plots for one-mouse show frequencies of 
CD5+CD19+ cells among total CD45+ cells. In a typical experiment, 80-100% of 
recipient mice develop CLL in 4-10 weeks after transfer of CLL cells. B) CLL cells 
were harvested from the peritoneal cavity or the spleen of Eμ-TCL1 or adoptive 
transfer mice. B-1 cells were isolated from the peritoneal cavity of C57BL/6J WT 
mice. Purified CD19+ CLL cells were obtained by using CD19+ microbeads and 
the autoMACS cell separator cell separation. Protein lysates from these cells 
were analyzed for the levels of TCL1 by Western blot. β-actin is used for loading 
control.
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Figure 3.2: Constitutive IL-10 production by CLL cells 
A) CLL cells were harvested from the spleen (n=23) or peritoneal cavity (n=5) of 
Eμ-TCL1 or adoptive transfer mice (n=9). B-1a cells were isolated from the 
peritoneal cavity of C57BL/6J WT mice (n=3). Purified CD19+ Eμ-TCL1 CLL cells 
were obtained by using CD19+ microbeads and the autoMACS cell separator cell 
separation. Cells were cultured for 24 hours (no stimulation) and IL-10 was 
measured in the supernatant by ELISA. B) Splenic CLL cells (n=7) were treated 
with or without LPS (5μg/ml) for 24 hours. Supernatant was collected and IL-10 
was measured by ELISA. Values represent mean ± SE of number of mice 
indicated. ***p<0.001 
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Figure 3.3D 
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Figure 3.3: Inhibiting IL-10 signaling does not affect the survival of the Eμ-
TCL1 CLL cells in vitro 
A) Splenic Eμ-TCL1 CLL cells were cultured with αIL-10 or αIL-10R antibodies 
with or without LPS (5μg/ml) for 48 hours. Survival of CLL cells was measured by 
MTT. Values represent mean ± SD of triplicate cultures. B) Splenic Eμ-TCL1 CLL 
cells were cultured with αIL-10 or αIL-10R antibodies with or without LPS 
(5μg/ml) for 48 hours. Tritiated thymidine was added at the last 4 hours of 
culture. Proliferation was measured by tritiated thymidine incorporation using a 
beta plate reader. Values represent mean ± SD of triplicate cultures. C) Eμ-TCL1 
CLL cells stained with anti-IL-10R or isotype control antibody and analyzed by 
flow cytometry. D) Protein lysates of Eμ-TCL1 CLL cells stimulated with 
exogenous IL-10 for indicated time points were analyzed for the levels of p-
STAT3 and total STAT3 by Western blot. β-actin is used for loading control. NS; 
not significant. 
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Summary 
 During the course of our studies, we made the observation that splenic 
cells isolated from our CLL model, the Eμ-TCL1 mouse, constitutively secreted 
IL-10. We found that peritoneal CLL cells also secrete IL-10 constitutively and 
that LPS enhances this IL-10 production. On average CLL cells from both spleen 
and peritoneal cavity produced similar amounts of IL-10. This is unlike normal B-
1 cells, wherein peritoneal but not splenic B-1 cells produced IL-10 constitutively 
or upon TLR4 stimulation. As discussed above, IL-10 secretion by normal B-1 
cells regulates their proliferation responses to TLR stimulation as well as BCR 
ligation. Here we found that neutralization of IL-10 using anti-IL-10 antibodies or 
anti-IL-10R antibody did not affect the survival or proliferation of the CLL cells 
despite the fact that IL-10 receptor appears to be functional in CLL cells. An 
interesting result seen here is the amount of variability of constitutive IL-10 
production by the different Eμ-TCL1 mice. This could be due to differences in VH 
subfamily expression between the different Eμ-TCL1 CLL cells. Hence, we 
sequenced a number of Eμ-TCL1 CLL cells for the expression of VH subfamilies. 
We found no linkage between the basal level of IL-10 and VH subfamily 
expression (unpublished data). Worth noting that studies performed in this work 
always used CLL cells that constitutively produced IL-10 with at least 150pg/ml 
levels. In future chapters we will be discussing if IL-10 has a function in the 
growth of CLL cells in vivo. 
 
Copyright © Sara Samir Alhakeem 2017 
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CHAPTER 4 
The role of IL-10 during immune responses to CLL 
 
 CLL is associated with a profound immune defect, which results in 
increased susceptibility to infections as well as a failure to mount effective 
antitumor immune responses. Infections in CLL patients have been recognized 
as a common cause of morbidity and mortality [13-15]. Many mechanisms of 
immunosuppression have been described in CLL. As seen in chapter 3, CLL cells 
constitutively produce IL-10, an immunosuppressive factor. However, CLL-
induced IL-10 had no effect on CLL cell survival in vitro. This led us to 
hypothesize that the CLL-derived IL-10 may have a suppressive effect on 
immune responses against CLL. IL-10 is known to regulate T cell responses 
indirectly through its effects on macrophages and monocytes, inhibiting their 
MHC class II and costimulatory molecule B7-1/B7-2 expression and limiting their 
production of proinflammatory cytokines and chemokines [79]. IL-10 can also act 
directly on T cells, inhibiting proliferation and production of IL-2, IFN-γ, IL-4, IL-5 
and TNF-α [81, 82]. Studies presented in this chapter investigate the role of 
adaptive immune responses in CLL and the effects of IL-10 on the 
microenvironment and T cell responses in CLL using the Eμ-TCL1 mouse model.  
 
  58 
 
Results 
(4a) Immune responses control CLL growth 
 CLL has been shown to be associated with defects in T-cell function, 
resulting in failure of antitumor immunity and increased susceptibility to infections 
[50]. Here we hypothesized that IL-10 could be playing a role in this T-cell 
dysfunction. First, we wanted to confirm the role of adaptive tumor immunity 
against CLL in the Eµ-TCL1 mouse model. Utilizing our CLL adoptive transfer 
model, we injected CLL cells into C57BL/6J wild type (WT) mice and NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice that lack mature B and T cells, as well as 
natural killer (NK) cells with secondary defects in macrophages and DCs [124, 
125]. We hypothesized that lack of adaptive immunity would lead to a change in 
the engraftment pattern of CLL cells. Indeed, comparing the percentage of 
CD5+CD19+ CLL cells in peripheral blood (PB), CLL cells in NSG mice were 
detectable as early as day 7 post injection (1-3% in CLL injected mice versus 
<0.15% in PBS injected NSG recipients) and had to be euthanized at day 16 due 
to poor body condition with an average of 70% CD5+CD19+ cells in PB (Figure 
4.1A). On the other hand, CLL cells were detectable only at day 21 post injection 
in WT mice and at day 28 an average of 50% CD5+CD19+ cells were present in 
PB (Figure 4.1A). The percentages of CLL cells in blood and spleen of both 
C57BL/6J and NSG mice at the time of euthanization are shown in Figure 4.1B. 
Kaplan-Meier analysis showed that upon CLL injection C57BL/6J mice survived 
longer than NSG mice (p<0.05) (Figure 4.1C), revealing an important role of 
adaptive immunity against CLL cells. 
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(4b) CLL cell growth is reduced in IL-10R null mice 
 Now that we confirmed the presence of anti-tumor immunity against CLL 
cells, we investigated if CLL-derived IL-10 could inhibit immune responses 
against CLL. In our hypothetical model as shown in Figure 4.2, IL-10 could be 
playing a role in inhibiting immune responses in CLL by either affecting innate 
immune cell functions in the CLL microenvironment such as their 
proinflammatory cytokine secretion or by directly affecting adaptive immune 
responses such as cytotoxic T cell role in anti-tumor immunity. To test this 
hypothesis, first using our adoptive transfer model, we injected CLL cells into WT 
and IL-10R KO mice both on the C57BL/6J background. Lack of IL-10 may 
enhance pro-inflammatory environment and increase CLL growth in IL-10R KO 
mice compared to wild type. For the possibility that IL-10 directly suppresses T 
cells, IL-10R KO mice will have more robust anti-CLL T cell responses leading to 
reduced CLL growth. Comparing the percentages of CD5+CD19+ CLL cells in PB 
of these mice, we found that CLL cells grew at a slower rate in IL-10R KO mice 
than in WT mice with the most difference at day 16 and day 20 (Figure 4.3A), 
though the differences in blood CLL levels between the two recipients at days 13, 
16, 20 and 25 were all statistically significant. After euthanization, CLL tumor 
burden in different tissues collected including spleen, bone marrow (BM), and 
peritoneal cavity (PC) was higher in WT mice than in IL-10R KO mice (p<0.05) 
(Figure 4.3B-D). Thus the presence of IL-10 signaling in WT mice appears to 
inhibit anti-tumor immunity leading to a higher growth rate and engraftment of 
CLL in these mice compared to mice unable to receive IL-10 mediated 
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immunosuppressive signals. Since it has been reported that at 12 weeks of age, 
approximately 60% of IL-10R KO mice develop chronic colitis and increased 
numbers of splenocytes resulting in splenomegaly [126], we performed our 
experiments soon after weaning, 3-4 weeks old mice. At the end of the 
experiment, colon sections from both WT and IL-10R KO mice showed no 
significant difference in inflammation by histopathology (Figure 4.3E). Moreover, 
there was no significant difference in plasma IL-10 levels between WT and IL-
10R KO mice at the end of the experiment (Figure 4.3F). 
 IL-10 is known to inhibit the function of macrophages and monocytes by 
limiting their production of proinflammatory cytokines and chemokines, which are 
thought to affect localization and survival of CLL cells in microenvironmental 
niches. We investigated this possibility in our model by testing if IL-10 is affecting 
the migration of CLL cells to the different mouse tissues in vivo. Using an 
adoptive transfer of CFSE labeled CLL cells, we found no significant difference in 
the total number of CFSE+ cells in the spleen, peritoneal cavity, bone marrow 
and lymph node between WT and IL-10R KO mice 3 days post injection, 
suggesting that differences in CLL growth in IL-10 sufficient and deficient mice 
are not due to any effects on early localization of the transferred cells (Figure 
4.4). 
(4c) Decrease in T-cell function in wild type compared to IL-10R null mice  
 We tested if the decrease in CLL growth in the IL-10R KO mice is due to 
changes in T cell levels and/or function. Indeed, frequencies of CD4+ and CD8+ T 
cells in the spleen were higher in the IL-10R KO mice in comparison to WT mice 
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injected with CLL (Figure 4.5). Therefore, to further understand the inhibitory 
effects of IL-10, we investigated the effects of CLL-derived IL-10 on T cell 
function during the course of the disease by measuring their ability to proliferate 
or secrete γ-IFN in response to stimulation with autologous CLL cells. We 
adoptively transferred CLL cells into WT and IL-10R KO mice and euthanized a 
set of mice at days 13 and 20 post injection. CD8+ cells were purified from the 
spleen of the mice using anti-CD8 antibody coupled microbeads. We found that 
proliferation of CD8+ cells isolated from IL-10R KO mice upon restimulation with 
irradiated CLL cells was significantly higher than proliferation of CD8+ T cells 
from WT mice at both time points (Figure 4.6A). CD8+ T cells isolated from IL-
10R KO mice exhibited a higher capacity to secrete IFN-γ than CD8+ T cells from 
WT mice upon restimulation with CLL cells in vitro (Figure 4.6B). In addition, 
intracellular staining of IFN-γ after a short-term (4 hours) stimulation ex vivo with 
PMA and ionomycin revealed higher percentages of both CD4+IFN-γ+ and 
CD8+IFN-γ+ cells in IL-10R KO in comparison to WT mice injected with CLL cells 
(Figure 4.6C). These data suggest a role for IL-10 in inhibiting T cell responses 
against CLL in vivo. 
(4d) T cells from IL-10R KO mice controlled CLL growth significantly longer than 
T cells from WT mice 
 To further demonstrate the functional differences between WT and IL-10R 
null T cells generated after CLL injection, we used the model of adoptive transfer 
of CLL cells into NSG mice. Here, we primed both WT and IL-10R KO mice with 
CLL cells. Then we isolated total T cells (Thy1.2+CD19-) from the spleens of the 
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mice after two weeks and adoptively transferred these T cells along with CLL 
cells used for priming into NSG mice at a ratio of one T cell to 8 CLL cells 
(experimental model shown in Figure 4.7). Overall, injection of T cells along with 
CLL cells delayed onset of disease in PB by a significant amount of time, no 
matter the source of the T cells (Figure 4.8A). At the time of euthanization, the 
number of CLL cells in the spleens indicated a difference between mice that 
received T cells from WT vs. IL-10R KO mice and was only significantly different 
between mice that received IL-10R KO T cells and mice that received no T cells 
(Figure 4.8B). 100% of the mice that received T cells from IL-10R KO mice 
survived at the end of the experiment while only 40% of the mice that received T 
cells from WT mice survived (Figure 4.8C). Thus IL-10R null T cells that cannot 
respond to IL-10 were more effective in controlling CLL disease than IL-10 
responsive wild type T cells. Similar results were obtained when NOG mice, an 
independently derived T cell, B cell and NK cell deficient mice, were injected with 
CLL cells and wild type or IL-10R KO T cells primed with CLL cells as above. The 
only difference was that the T cell to CLL ratio was decreased to 1:16. Despite 
this lower T cell to CLL ratio, none of the mice receiving CLL primed IL-10R null 
T cells developed CLL even after 184 days while only three out of five mice 
receiving primed wild type T cells developed CLL by day 50. All the NOG 
recipients receiving CLL cells without any T cells developed CLL by day 27.  
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(4e) The adoptive transfer of CD8+ T cells was sufficient in controlling CLL 
development and CD8+ T cells from IL-10R KO mice controlled CLL growth 
significantly longer than T cells from WT mice 
 To help us identify the possible subset of T cells responsible for the anti-
CLL immune response, we injected isolated CD8+ T cells from WT and IL-10R 
KO mice primed with CLL as above along with CLL cells at a ratio of 1 T cell to 
32 CLL cells into NSG mice. Interestingly, CD8+ T cells were sufficient in 
delaying CLL growth and CD8+ T cells from IL-10R KO mice were better at 
controlling disease development than CD8+ T cells from WT mice (Figure 4.9A). 
At the time of euthanization, the number of CLL cells in the spleens indicated a 
significant difference between mice that received CD8+ T cells from WT vs. IL-
10R KO mice; however, no significant difference was observed between group 
receiving T cells from IL-10R KO mice and PBS control mice (Figure 4.9B). 100% 
of the mice that received No T cells or CD8+ T cells from WT mice developed 
disease by day 30 post injection while only 16.7% of the mice that received CD8+ 
T cells from IL-10R KO mice developed disease by that time (Figure 4.9C). 
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Figure 4.1: Lack of B, T and NK cells leads to an acceleration of CLL growth 
kinetics 
A) Eμ-TCL1 CLL cells (4 x 106) were adoptively transferred into WT and NSG 
mice by retro-orbital injection. Leukemic status is determined by weekly 
submandibular bleeding. Graph shows the % CD5+CD19+ cells in the peripheral 
blood at indicated time points. Values represent arithmetic mean of six mice per 
group ± SD. B) % CD5+CD19+ cells in the spleen of C57BL/6 and NSG mice is 
analyzed at the time of euthanization by flow cytometry. Values represent 
arithmetic mean of values from six recipient mice per group ± SD. C) Kaplan-
Meier blot represents the survival of C57BL/6 and NSG mice during the course of 
the experiment (n=6). * p< 0.05 determined by Student’s t-test for panels A and B 
and by Log-rank (Mantel-Cox) test for panel C. Similar results were obtained in 
another experiment. 
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Figure 4.2: Hypothetical model for the effects of IL-10 on the immune 
system in CLL
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Figure 4.3: CLL cell growth rate is reduced in IL-10R null mice 
A) Eμ-TCL1 CLL cells (4 x 106) were adoptively transferred into WT and IL-10R 
KO mice by retro-orbital injection (n=5 mice/group). Leukemia status was 
monitored by weekly bleeding and is shown as CD5+ CD19+ cells as a 
percentage of CD45+ cells in the peripheral blood. Injection of PBS was used as 
a control. B-D) Tumor burden as total number of CD5+ CD19+ cells was 
calculated based on total cell count and % of CD5+ CD19+ cells per spleen (B), 
bone marrow (C) and peritoneal cavity lavage (D). Values represent arithmetic 
mean of five mice per group ± SD. *p< 0.05. E) Representative colon H & E 
staining from WT and IL-10R KO mice injected with CLL cells or PBS. Colon 
sections were scored as described in the methods. NS; not significant. F) IL-10 
plasma levels from WT and IL-10R KO mice were determined by ELISA at the 
end of the experiment. 
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Figure 4.4: No differences in localization of CLL cells between WT and IL-
10R KO mice 
Eμ-TCL1 CLL cells were labeled with CFSE (10μM/ml) and adoptively transferred 
into WT and IL-10R KO mice by retro-orbital injection (n=4/group). Mice were 
euthanized 3 days post injection and indicated tissues were harvested and 
stained for CD5 and CD19. Total numbers of CFSE+ CLL cells are represented. 
Injection of PBS was used as a control. Values represent arithmetic mean of four 
replicates ± SD. NS; not significant. Results from one of three experiments with 
similar outcome are shown. 
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Figure 4.5: Frequency of T cells are reduced in WT mice in compare to IL-
10R KO mice injected with CLL 
Eμ-TCL1 CLL cells (4 x 106) were adoptively transferred into WT and IL-10R KO 
mice by retro-orbital injection. At Day 23 post injection, mice were euthanized 
and splenic cells were stained for CD4 and CD8. Frequencies of CD4+CD8- cells 
(Top) and CD4-CD8+ cells (Bottom) are indicated. Values represent arithmetic 
mean of data from five mice per group ± SD. *p< 0.05. 
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Figure 4.6A 
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Figure 4.6: IL-10 caused a decrease in T cell function in mice injected with 
CLL cells 
CD8+ cells were purified from spleen of WT and IL-10R KO mice using CD8+ 
microbeads 13 and 20 days post CLL injection. CD8+ cells were cultured alone or 
with irradiated 1 x 105 CLL cells at a ratio of 1:2 or 1:1 for 72 hours. (A) Tritiated 
thymidine was added to culture in the last 4 hours and proliferation was 
measured by 3[H] incorporation using a beta plate counter. Values represent 
mean ± SD of triplicate cultures. B) CD8+ cells were cultured with irradiated CLL 
cells at a ratio of 1:2 or 1:1 for 24 hours. Supernatant was collected and IFN-γ 
was measured by ELISA. Values represent mean ± SD of triplicate cultures. C) 
Surface staining for CD4 (top panel) and CD8 (bottom panel) and intracellular 
staining of IFN-γ was performed on splenic cells from WT and IL-10R KO mice 
obtained 13 and 20 days post CLL injection. Cells were stimulated for 4 hours 
with PMA and ionomycin before staining. Values represent arithmetic mean of 
four recipient mice ± SE. *p< 0.05. Representative results from one of two 
experiments are shown. 
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Figure 4.7: Experimental model for T cell adoptive transfer experiment 
1. Inject CLL cells into WT and 
IL-10R KO to prime the T cells 
2. Two weeks post injection; purify T 
cells (Thy1.2+CD19- cells) from the 
spleen by flow cytometry sorting 
C57BL/6 (WT) IL-10R KO  
3. Inject CLL along with T cells into NSG 
mice (1:8) ratio of T cells: CLL cells 
NSG  
4. Monitor CLL growth 
Prediction: Engraftment of CLL will be lower/slower in the mice 
that received T cells from IL-10R KO mice. 
Figure 4.7 
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Figure 4.8: Adoptive transfer of CLL primed T cells delayed CLL growth  
A) WT and IL-10R KO mice received an IV injection of CLL cells. 17 days post 
injection; Thy1.2+ cells from the CLL recipient mice were sorted by flow 
cytometry. CLL cells and Thy1.2 cells were then injected into NSG mice at a ratio 
of one T cell to 8 CLL cells and leukemic status was monitored by staining for 
CD5+CD19+ cells in the blood at the time points indicated. Values represent 
mean values ± SE (n= 4-5 recipients). B) #CD5+ CD19+ cells are determined in 
the spleen of NSG mice at the time of euthanization. C) Bar graph representing 
the percentage of mice that developed CLL from each group at the end of the 
experiment.  
  80 
 
Figure 4.9A 
Figure 4.9B 
Figure 4.9C 
14 21 28 30
0
50
100
150
Days Post Injection
%
 C
D
5+
 C
D
19
+ 
WT CD8+ T cells primed with CLL
IL-10R KO CD8+ T cells primed with CLL
PBS
No T cells
** *
WT
 CD
8+
 T 
ce
lls
 
pri
me
d w
ith
 CL
L
IL-
10
R K
O C
D8
+ T
 ce
lls
 pr
im
ed
 wi
th 
CL
L
No
 T 
ce
lls
0
50
100
150
%
 M
ic
e 
th
at
 d
ev
el
op
ed
 C
LL
No
 T 
ce
lls
WT
 CD
8+
 T 
ce
lls
 pr
im
ed
 wi
th 
CL
L
IL-
10
R K
O C
D8
+ T
 ce
lls
 
pri
me
d w
ith
 CL
L
PB
S
0
2×108
4×108
6×108
8×108
1×109
# 
C
D
5+
 C
D
19
+ / 
Sp
le
en
  
***
***
*
**
NS
  81 
 
Figure 4.9: The adoptive transfer of CLL primed CD8+ T cells was sufficient 
in delaying CLL growth  
A) WT and IL-10R KO mice received an IV injection of CLL cells. 14 days post 
injection; CD8+ cells from the CLL recipient mice were isolated with CD8+ 
microbeads and the autoMACS cell separator. CLL cells and CD8+ T cells were 
then injected into NSG mice at a ratio of one T cell to 32 CLL cells and leukemic 
status was monitored by staining for CD5+CD19+ cells in the blood at the time 
points indicated. Values represent mean values ± SE (n=6 recipients). The 
significance indicated is by comparing the WT CD8+ T cells primed with CLL and 
the IL-10R KO CD8+ T cells primed with CLL groups. B) #CD5+ CD19+ cells are 
determined in the spleen of NSG mice at the time of euthanization. C) Bar graph 
representing the percentage of mice that developed CLL from each group at the 
end of the experiment. *p< 0.05, p**< 0.01, p***< 0.001, NS; not significant. 
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Summary 
 The immune system plays an important role in controlling tumor 
progression. Effective antitumor immune response depends on close interaction 
of several elements of the immune system. These include antigen-presenting 
cells, different subsets of T cells, B cells and NK cells. Here as predicted we 
found that adaptive immune responses played a significant role in chronic 
lymphocytic leukemia. CLL cell growth in vivo was significantly faster in mice that 
lacked B, T and NK cells in comparison to WT mice with intact immune system. 
However, eventually CLL cells, given enough time, are able to engraft tissues of 
the wild type mice equally, which indicates that tumor cells develop a number of 
mechanisms to escape recognition and elimination by immune system. CLL cells 
are capable of producing the immunosuppressive protein, IL-10, constitutively. 
Initially, we observed that engraftment of CLL cells in comparison to WT mice 
was significantly lower in IL-10R KO mice, in which IL-10 is unable to carry out its 
immunosuppressive functions. Since IL-10 has been known for its effects on a 
number of immune cells including APCs and T cells, we first tested if the 
difference in engraftment was due to IL-10 effects on APCs. Macrophages and 
monocytes are known to secrete many cytokines and chemokines that affect the 
localization and survival of CLL cells in the microenvironment. Although is our 
studies we found no significant difference in CLL cell-localization in IL-10 
sufficient and deficient mice, we cannot eliminate the role of these innate cells in 
CLL. Future studies will investigate the inhibitory effects IL-10 might have on 
macrophages and monocytes in the CLL model. Next, we examined the effects 
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of IL-10 on T cell responses in CLL model. We found that the proliferation of T 
cells isolated from IL-10R KO mice upon restimulation with irradiated CLL cells 
was significantly higher than proliferation of T cells from WT mice. In addition, 
CD8+ T cells isolated from IL-10R KO mice exhibited a higher capacity to secrete 
IFN-γ than CD8+ T cells from WT mice injected with CLL cells. Finally, upon 
transfer of primed T cells from both WT and IL-10R KO mice into CLL-injected 
NSG mice, T cells were able to delay the progression of CLL, where T cells from 
IL-10R KO mice were more effective. Interestingly, CD8+ T cells were sufficient 
in delaying CLL disease development and CD8+ T cells isolated from IL-10R KO 
primed with CLL were significantly better at controlling CLL growth than CD8+ T 
cells isolated from WT mice. Future studies will need to investigate if CD4+ T 
cells have similar effects in controlling CLL growth.  
 
 
 
 
 
 
 
 
 
 
Copyright © Sara Samir Alhakeem 2017 
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CHAPTER 5 
Role of BCR signaling in constitutive and induced IL-10 production by CLL 
cells and a novel role of Sp1 in regulating IL-10 production by CLL B cells 
 After having established a role for IL-10 in CLL growth, we investigated 
the possibility of targeting IL-10 to overcome its immunosuppressive effects. 
Therefore, we aimed to identify the possible mechanisms by which IL-10 is 
produced constitutively by CLL cells, which may help identify targets to prevent 
IL-10 production and immunosuppression associated with it. The molecular 
mechanisms involved in IL-10 production by many cells of the immune system 
have been extensively studied, however, it is not clear whether the molecular 
mechanisms required for the induction of IL-10 by B cells are regulated by the 
same factors that regulate IL-10 production by T helper cells, macrophages and 
DCs. Due to the importance of tonic B cell receptor signaling in the survival of 
normal B cells, as well as its impact on the survival and growth of malignant B-
cell clones in CLL and in other non-Hodgkins lymphomas, here we investigated 
the role of BCR signaling in IL-10 production by CLL cells [98-101]. We 
discovered a novel role of BCR signaling in IL-10 production by CLL cells [54]. 
BCR dependent constitutive activation of Src or Syk family kinase is required for 
constitutive IL-10 production by both mouse and human CLL cells. This work to 
understand the molecular pathways leading to IL-10 production CLL cells by 
BCR signaling would provide valuable information on possible targets for IL-10 
manipulation and modulation of the immune response in CLL.
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Results 
(5a) The novel role of BCR signaling in IL-10 production by Eμ-TCL1 CLL cells  
 During our preliminary studies, we were able to establish a novel role of 
BCR signaling in IL-10 production by normal B-1 and malignant Eμ-TCL1 CLL 
cells (Figure 5.1). For the majority of our Eμ-TCL1 CLL cells, crosslinking the 
BCR with anti-IgM led to an increase in IL-10 production (Figure 5.1A). Inhibition 
of Src, Btk or Syk family kinases that are essential for signal transduction via 
BCR reduced both constitutive and anti-IgM induced IL-10 production by Eμ-
TCL1 CLL cells in a dose dependent manner (Figure 5.1B). 
 Additionally, we utilized a human CLL cell line called MEC1 cells in our 
studies. MEC1 cells grew spontaneously from the peripheral blood of a patient 
with CLL in prolymphocytoid transformation [127]. MEC1 cell line expresses the 
same light and heavy chains as the parental CLL cells with similar intensity. 
MEC1 cells are CD19+, CD20+, CD21+ and CD22+. However, MEC1 cells are 
CD5- but also produce IL-10 constitutively and IL-10 was found to be regulated by 
BCR signaling in MEC1. Constitutive production of IL-10 by MEC1 cells is 
diminished by Src, Syk or Btk inhibition (Figure 5.1C). Here we also opted to use 
MEC1 cells in our gene silencing experiments due to the difficulties we faced in 
transfecting primary mouse or human CLL cells. We used a short hairpin RNA 
(shRNA) to knock down Lyn, a Src family kinase and one of the earliest enzymes 
activated with BCR cross-linking. MEC1 cells with 50% lyn knock-down produced 
less IL-10 than control shRNA treated cells (Figure 5.1D). Stimulation of Eμ-
TCL1 CLL cells by BCR cross-linking led to an increase of IL-10 mRNA levels 
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and inhibition of Syk reduced those levels (Figure 5.1E), suggesting that IL-10 
production is controlled at the transcript level. To further verify IL-10 production 
by Eμ-TCL1 cells, we performed IL-10 intracellular staining. 60-80% of Eμ-TCL1 
CLL cells were IL-10 producers, which was reduced by Syk inhibition (Figure 
5.2).  
(5b) IL-10 production by Eμ-TCL1 CLL cells is dependent on ERK1/2 MAPK and 
the transcription factor Sp1 but not on p38MAPK or STAT3 
Importance of P38/MAPK and STAT3 was tested since they are known to 
be involved in IL-10 production by myeloid cells. Surprisingly, phosphorylation of 
the P38/MAPK or the transcription factor STAT3 was not affected by Syk 
inhibition (Figure 5.3A). On the other hand, phosphorylation of extracellular 
signal-regulated kinase 1/2 (ERK1/2) was reduced after the inhibition of Syk 
(Figure 5.3A). In order to find a possible downstream transcription factor, which is 
involved in BCR induced IL-10 production, we tested the transcript levels of 
multiple transcription factors known to be required for IL-10 transcription in 
various immune cells. These included SMAD4, GATA3, CREB, ATF1 and Sp1 
[84]. None of these transcription factors except Sp1 were regulated by BCR 
signaling, as their transcript levels did not change upon stimulation with anti-IgM 
(Figure 5.3B). Sp1 was the only tested transcription factor found to be 
significantly enhanced by BCR signaling and reduced by Syk inhibition (Figure 
5.3C). Treatment of Eμ-TCL1 CLL cells with Mithramycin A, a well-known 
inhibitor of Sp1 [128], reduced IL-10 protein levels in a dose dependent manner 
(Figure 5.3D-E). Sp1 is proposed to bind and transactivate IL10 gene in 
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macrophages and T cells [129]. To further establish its role in IL-10 transcription 
in CLL cells, we utilized chromatin immunoprecipitation (ChIP) to test if Sp1 binds 
to the IL-10 promoter in CLL cells. RT-PCR of the ChIP product revealed 8-fold 
enrichment in binding of Sp1 to IL-10 promoter over the input sample (Figure 
5.3F). Taken together, these results indicate that IL-10 production by Eμ-TCL1 
CLL cells is dependent on the transcription factor Sp1. 
Previous studies have indicated the important role of ERK1/2 in Sp1 
activation [130]. Since we already showed that ERK1/2 activation is regulated by 
BCR signaling (Figure 5.3A), we hypothesized that ERK1/2 activation is the link 
between BCR and Sp1. Accordingly, treatment of Eμ-TCL1 CLL cells with 
SCH772984, a specific ERK1/2 inhibitor decreased IL-10 production in a dose-
dependent manner (Figure 5.4A). Interestingly, Sp1 protein levels were also 
reduced upon ERK1/2 inhibition (Figure 5.4B). Also, consistent with data using 
Syk inhibitor, ERK1/2 inhibitor did not affect the activation of STAT3 (Figure 
5.4B). To demonstrate a better correlation between reduced ERK1/2 
phosphorylation and Sp1 levels, we measured Sp1 transcript levels after ERK1/2 
inhibition and found that Sp1 mRNA was significantly reduced after ERK1/2 
inhibition (Figure 5.4C). This suggests that IL-10 production by CLL cells is 
regulated by the activation of ERK1/2 and subsequent activation of Sp1 leading 
to IL-10 transcription. 
(5c) BCR signaling regulates IL-10 production by human CLL cells 
We tested the role of BCR signaling in IL-10 production by human CLL 
cells. Table 5.1 summarizes the properties of the CLL patients’ donor pool. 
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Peripheral blood mononuclear cells (PBMCs) from CLL patients produced a 
significant amount of IL-10 only after LPS stimulation or BCR cross-linking in 
comparison to normal human PBMCs, with very little constitutive production 
(Figure 5.5A). BCR cross-linking with anti-IgM leads to increased IL-10 
production by human CLL cells in a dose dependent manner (Figure 5.5B). 
There was a significant amount of IL-10 in the plasma of CLL patients while it 
was nearly undetectable in healthy age matched individuals, though there was 
some variability (Figure 5.5C). In addition, neutralization of LPS or anti-IgM 
induced-IL-10 did not affect the survival of human CLL cells (Figure 5.5D), 
consistent with data seen using mouse CLL cells (Figure 3.3). Inhibition of Src, 
Syk family kinases or Btk led to the complete abrogation of anti-IgM induced IL-
10 production by human CLL cells (Figure 5.5E). Similar to mouse CLL cells, 
inhibition of BCR signaling in human CLL reduced ERK1/2 activation, Sp1 activity 
and IL-10 levels (Figure 5.5F). 
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Figure 5.1: The role of BCR signaling in IL-10 production by Eμ-TCL1 CLL 
cells 
A) Normal peritoneal B-1 cells (Left) and Eμ-TCL1 CLL cells (Right) were 
cultured with or without αIgM (25μg/ml) for 24 hours. Supernatants were 
collected and IL-10 levels were measured by ELISA. Each line represents a 
single clone of Eμ-TCL1 CLL cells (clone=cells from one individual Eμ-TCL1 
mouse) B) Eμ-TCL1 CLL cells were cultured without (top) or with (bottom) αIgM 
(25μg/ml) and then treated with indicated doses of dasatinib (A SRC family 
kinase inhibitor), Syk inhibitor IV (BAY 61-3606) or Btk inhibitor (Ibrutinib) for 24 
hours. Supernatants were collected and IL-10 levels are measured by ELISA. 
Values are normalized to the no drug control and set to 100%. Values represent 
mean ± SD of triplicate cultures. Results are representative of 4-8 experiments. 
C) MEC1 cells were cultured with inhibitors indicated as in Panel B and 
supernatants were collected after 24 hours. IL-10 levels were measured by 
ELISA. Values represent mean ± SD of triplicate cultures. Results are 
representative of two experiments. D) Western blot showing a reduction in Lyn in 
MEC1 cells expressing Lyn specific shRNA. Lyn protein values were normalized 
to β-actin (Left). IL-10 levels were measured in the supernatant of MEC1 cells 
expressing either control shRNA or Lyn shRNA (Right). E) IL-10 mRNA levels 
are determined by qRT-PCR in Eμ-TCL1 CLL cells treated with or without αIgM 
(25μg/ml) in the presence or absence of Syk inhibitor IV (5μM) for time points 
indicated. IL-10 mRNA expression was normalized to mouse 18S RNA. Values 
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represent mean ± SD of triplicate determinations. *p< 0.05. Results are 
representative of 2-4 experiments. 
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Figure 5.2: Syk inhibition leads to decrease in the number of IL-10 
producing CLL cells 
Eμ-TCL1 CLL cells were cultured with or without Syk inhibitor IV (2μM) for 24 
hours. Then stimulated with PMA (20ng/ml) and Ionomycin (1μg/ml) for 4 hours 
and intracellular IL-10 staining was performed. A representative IL-10 histogram 
overlay of unstained, untreated, and Syk inhibitor treated samples after gating on 
viable CD5+ CD19+ cells is shown on the top. The bar graph represents an 
average of IL-10 intracellular staining of 3 Eμ-TCL1 mice CLL cells with or 
without Syk inhibition (bottom). Values represent mean ± SEM. 
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Figure 5.3: IL-10 production by Eμ-TCL1 CLL cells is dependent on ERK1/2 
MAPK and the transcription factor Sp1 but not on p38MAPK or STAT3 
A) Eμ-TCL1 CLL cells were treated with 5μM of Syk inhibitor IV for indicated time 
periods. Levels of p-Syk, total Syk, p-P38 MAPK, total P38 MAPK, p-ERK1/2, 
total ERK1/2, p-STAT3, and total STAT3 were quantified by Western blot. 
Phospho-protein levels were normalized to total protein. Total protein levels were 
normalized to β-actin. Numbers indicate quantification of band intensity by 
ImageJ software. Results are representative of three experiments. B) mRNA 
levels of transcripts indicted were quantified by qRT-PCR after treatment of Eμ-
TCL1 CLL cells with αIgM (25μg/ml) for 1, 4, or 6 hours. Fold change was 
normalized to the no-treatment group (dashed line). Values represent mean ± SD 
of triplicate determinations. C) Sp1 mRNA levels were quantified by qRT-PCR 
after treatment of Eμ-TCL1 CLL cells with αIgM (25μg/ml) or Syk inhibitor IV 
(5μM) for 1, 4, or 6 hours. Fold change was normalized to the no-treatment 
group. Values represent mean ± SD of triplicate determinations. D) Eμ-TCL1 CLL 
cells were treated with various doses of mithramycin A, an Sp1 inhibitor for 24 
hours. Culture supernatants were collected and IL-10 was measured by ELISA. 
E) Western blot analysis of IL-10 protein levels in CLL cells after treatment with 
mithramycin A (5μM) for indicated time points. GAPDH was used for loading 
control. F) ChIP was carried out as described in the methods. Antibodies against 
Sp1 and IgG (control) were used for Chromatin IP. qRT-PCR was performed on 
the ChIP DNA product using primers specific for the consensus Sp1 binding site 
sequence in the IL-10 promoter. Data is calculated using the Fold Enrichment 
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Method. This normalization method is relative to the no-antibody control (2% 
input sample). *p< 0.05, ***p<0.001 
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Figure 5.4: ERK1/2 inhibition leads to Sp1 degradation and inhibition of IL-
10 production in CLL cells 
A) Eμ-TCL1 CLL cells were cultured with the ERK1/2 inhibitor (SCH772984) and 
supernatants were collected after 24 hours. IL-10 levels were measured by 
ELISA. Values represent mean ± SD of triplicate cultures. B) Eμ-TCL1 CLL cells 
were treated with ERK1/2 inhibitor (2μM) for indicated time points. Levels of p-
ERK1/2, total ERK1, p-STAT3, total STAT3 and Sp1 were quantified by Western 
blot analysis. β-actin was used for loading control. Results are representative of 
three experiments. C) Sp1 mRNA levels were quantified by qRT-PCR after 
treatment of Eμ-TCL1 CLL cells with ERK1/2 inhibitor (2μM) for 1, 4, or 6 hours. 
Fold change was normalized to the no-treatment group. Values represent mean 
± SD of triplicate determinations. ***p<0.001 
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Patient# Age Sex WBC (K/µL) 
%CD5+ 
CD19+ 
CD38 
Status Treatment 
IGHV 
mutation 
1 82 F 20.7 90.54 Negative No M-CLL 
2 56 F  ND 82.35 ND No U-CLL 
3 36 M 38.3 88.08 Negative No M-CLL 
4 46 M 41 44.01 Negative No M-CLL 
5 52 M 15.2 81.37 ND Yes M-CLL 
6 69 M 29 83.88 Positive No M-CLL 
7 57 M 40 50.33 ND Yes U-CLL 
8 62 F 83.7 10.55 ND No U-CLL 
9 69 M 30.2 95.71 ND No M-CLL 
10 70 M 17.4 80.45 ND No M-CLL 
11 63 M 34.8 96.97 ND No M-CLL 
12 53 M 12.1 84.73 Positive Yes U-CLL 
13 55 M 6 13.64 ND Yes M-CLL 
14 76 F 36.6 37.23 ND Yes M-CLL 
15 80 M 142 97.73 ND Yes U-CLL 
Table 5.1: Properties of the CLL patients’ donor pool 
ND; Not determined 
  102 
 
 
Figure 5.5A 
Figure 5.5B 
Media LPS anti-IgM
0
100
200
300
400
500
IL
-1
0 
(p
g/
m
l)
Human CLL PB cells
Normal human PB cells
*
*
0.001 0.01 0.1 1 10
0
20
40
60
80
αIgM (µg/ml)
IL
-1
0 
(p
g/
m
l)
Human CLL P#2
Human CLL P#3
Figure 5.5C 
Human CLL
Plasma
Human normal
Plasma
-50
0
50
200
400
600
800
IL
-1
0 
(p
g/
m
l)
  103 
 
 
Media LPS αIgM
0.0
0.2
0.4
0.6
0.8
O
pt
ic
al
 D
en
si
ty
 (5
60
-6
90
) No Treatment
α-IL-10 (10µg/ml)
α-IL-10R (10µg/ml)
NS
NS
Figure 5.5D 
Figure 5.5E 
Figure 5.5F 
No
 In
hib
ito
r
Bt
k i
nh
ibi
tor
Sy
k I
nh
ibi
tor
Da
sa
tin
ib
0
10
20
30
40
50
IL
-1
0 
(p
g/
m
l) αIgM induced IL-10 
+ - 
2 hrs 
5μM BAY 61-3606 0hr - 
1 hr 
+ - 
4 hrs 
+ - 
6 hrs 
+ 
IL-10 
β-actin 
SP-1 
p-ERK1/2 
Total ERK1 
  104 
 
Figure 5.5: Human CLL cells share similar mechanisms to mouse CLL cells 
for IL-10 production  
A) Human CLL cells obtained from peripheral blood of CLL patients were 
cultured and stimulated with LPS (5μg/ml) or αIgM (25μg/ml) for 24 hours. IL-10 
was measured in the supernatant of the cells by ELISA. Values represent mean 
± SD of triplicate cultures. B) Human CLL cells were cultured and stimulated with 
increasing doses of αIgM for 24 hours. IL-10 was measured in the supernatant of 
the cells by ELISA. The graph represents data from 2 human CLL samples. 
Values represent mean ± SD of triplicate cultures. C) Human CLL patients (n=16) 
as well as normal donors (n=28) plasma levels of IL-10 were measured by ELISA 
(n=16). D) Human CLL cells were cultured with αIL-10 or αIL-10R antibodies with 
or without LPS (5μg/ml) or anti-IgM (25μg/ml) for 48 hours. Survival of CLL cells 
were measured by MTT. Values represent mean ± SD of triplicate cultures. NS; 
not significant. E) Human CLL cells stimulated with αIgM (25μg/ml) and treated 
with or without Btk inhibitor, Syk inhibitor or dasatinib for 24 hours. Supernatants 
were collected and IL-10 levels were measured by ELISA. Values represent 
mean ± SD of triplicate cultures. F) Human CLL cells were treated with Syk 
inhibitor (5μM) for indicated time points. Levels of p-ERK1/2, total ERK1, Sp1 
and IL-10 were quantified by Western blot analysis. β-actin was used for loading 
control. Results were reproducible with 3 CLL patient samples.  
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Summary 
 In this chapter we demonstrated a novel role of BCR signaling in the 
constitutive production of IL-10. Since BCR signaling is important in CLL 
subtypes such as U-CLL, BCR-induced IL-10 could be a factor in their more 
aggressive nature. We found that inhibition of the major kinases in the BCR 
signaling pathway including Src, Syk and Btk leads to the significant reduction of 
IL-10 production by Eμ-TCL1 CLL cells. We also discovered that inhibition of 
BCR signaling led to a decrease in ERK1/2 MAP kinase activation, which is 
consistent with a role for ERK1/2 in IL-10 production seen in T cells [84]. 
However, BCR signaling mediated IL-10 production was STAT3 independent. In 
addition, we were able to reveal a novel role for the transcription factor Sp1 in 
BCR signaling dependent IL-10 production by Eμ-TCL1 CLL cells. Sp1 was 
found to bind to the IL-10 promoter in Eμ-TCL1 cells and inhibition of Sp1 led to a 
decrease in IL-10 production in a dose dependent manner. We were also able to 
link the activation of ERK1/2 to Sp1 activity, which is consistent with regulation of 
Sp1 by ERK1/2 in other cell types [130, 131]. We found that ERK1/2 inhibition 
leads to Sp1 degradation and inhibition of IL-10 production in both murine and 
human CLL cells. Many studies have indicated that phosphorylation, acetylation, 
sumoylation, ubiquitination and glycosylation are among the posttranslational 
modifications that influence the transcription activity and stability of Sp1 [132]. 
For example, recent studies indicated that c-Jun NH(2)-terminal kinase 1 (JNK1) 
phosphorylates Sp1 at Thr278 and Thr739, protecting Sp1 from ubiquitin-
dependent degradation and increase its stability during mitosis in tumor cells 
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lines [133]. Here since we demonstrate that ERK1/2 inhibition leads to 
degradation of both RNA and protein levels of Sp1, we hypothesize that ERK1/2 
might be controlling Sp1 RNA stability in CLL cells. To test this hypothesis, we 
will utilize luciferase assay using a plasmid expressing the promoter for Sp1. 
After transfecting the plasmid in our CLL cells, we will use the ERK1/2 inhibitor to 
determine its effects on Sp1 transcription. The regulation of IL-10 production by 
mouse CLL cells was found to be similar in human CLL cells. Despite the fact 
that there are significantly higher levels of plasma IL-10 in human CLL patients 
compared to healthy donors, PBMCs from human CLL patients do not 
constitutively produce IL-10. However, treatment with anti-IgM leads to an 
increase in IL-10 production by human CLL cells, which is completely abrogated 
by the inhibition of kinases in the BCR signaling pathway. As seen in the murine 
system B cells from healthy human patients, which are likely to be B-2 cell 
population produce very little IL-10 even after stimulation by BCR cross-linking. 
Moreover, similar to mouse CLL cells, inhibition of BCR signaling in human CLL 
reduced ERK1/2 activation, Sp1 activity and IL-10 levels.  
 
 
 
 
 
 
Copyright © Sara Samir Alhakeem 2017 
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CHAPTER 6 
Discussion 
 Immune cells and humoral factors comprise two intertwined systems, 
innate and acquired. Immune cells scan the existence of any molecule that is 
considered to be nonself, which include nonself antigens presented by cancer 
cells. A specific immune response is generated, which results in the proliferation 
of antigen-specific lymphocytes. Immunity is considered acquired when antigen 
specific antibodies and T cells are upregulated. Both innate and acquired 
immune systems interact to initiate antigenic responses against tumors. A key 
driver of anti-tumor immunity is T cell. Many important discoveries had led to an 
increase in our understanding of the role of T cells in cancer. T cells are either 
cytotoxic (CD8+) or helper (CD4+). CD8+ T cells react with peptide antigens that 
have been digested from endogenous proteins and presented by MHC molecules 
on the surface of cells. CD8+ T cells then destroy the cell by perforating its 
membrane and by delivering apoptosis triggering molecules. The CD8+ T cell will 
move to another cell expressing the same MHC-peptide complex and destroys it 
as well. Ideally, CD8+ T cells create a very specific and robust response against 
tumor cells. Cytotoxic T cells are considered to be essential effectors of the cell-
mediated immune response. The ability to identify and destroy tumors as a 
central part of the immune system function is defined as the immune surveillance 
theory, which was put forward in the 1960s [134]. Later on, the theory received 
major doubts as a study demonstrated no increase in tumor incidence in athymic 
nude mice [135]. However, extensive work in the last couple of decades has 
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shown that athymic nude mice were not necessarily an appropriate model for 
studying immune surveillance due to the fact that nude mice do not completely 
lack functional T cells. On the other hand, the use of genetically modified mice 
generating defined and stable immune defects has fully supported the theory of 
surveillance. For example, mice with genetic alterations leading to deficiencies in 
B and T cells are more prone to spontaneous and induced carcinogenesis than 
wild type mice [136]. In addition, patients with acquired immune deficiencies such 
as acquired immune deficiency syndrome (AIDS) and post transplant immune 
suppression display a dramatic increase in the incidence of several tumor types, 
including lymphoid tumors, lung cancer and tumors related to viral infections 
[137]. Immune surveillance mechanisms are ideal for limiting cancer 
development; unfortunately, they are not completely efficient. Tumors that 
eventually arise are typically poorly or not immunogenic [138]. Lately, it has been 
become evident that a tumor can develop many defense mechanisms an 
immune attack. The ability to evade the immune response is a major hallmark of 
cancer [139].  
 Now, it is well established that the development of cancer is associated 
with alterations in the number and function of immune cells in the periphery and 
especially at the sites of tumor progression. In this dissertation work, I studied B 
cell chronic lymphocytic leukemia, which is a disease caused by a clonal 
expansion of small, mature B lymphocytes. Although it is often detected as a 
consequence of a lymphocytosis in otherwise asymptomatic patients, patients 
with more advanced disease can exhibit a variety of symptoms including weight 
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loss, sweats, lymphadenopathy, splenomegaly, and bone marrow failure [2]. A 
major feature of CLL is that patients are susceptible to recurrent infections, which 
are a major cause of morbidity and mortality in this disease [13, 14]. The goal of 
this study was to further investigate the underlying reasons for the 
immunosuppression seen in CLL patients as well as to identify mechanisms that 
could be used to enhance immune responses against CLL. 
(6a) Immunosuppression in chronic lymphocytic leukemia 
 The immune deficiency seen in CLL is quite varied, resulting in increased 
susceptibility to bacterial, viral and fungal infections and failure to mount an 
effective antitumor immune response [13, 14]. Nevertheless, one of the earliest 
observations of the immune system in CLL is an increase in the number of 
circulating T cells, which is primarily accounted for by an increased number of 
CD8+ T cells, resulting in a decreased CD4:CD8 ratio [46, 140, 141]. These T 
cells show diverse phenotypic and functional abnormalities. Phenotypically, they 
show an increase in CD57, CD69 and HLA-DR expression as well as a decrease 
in CD28 and CD62L expression, which suggest activation and a shift towards a 
differentiated effector-memory subtype [142, 143]. Other studies demonstrated 
oligoclonal expansions of both CD4+ and CD8+ T cells, specifically within the 
CD57+ subset [49, 144-146]. Interestingly, it has also been shown that T cells 
from CLL patients have specificity for cytomegalovirus (CMV), in which these 
CMV-specific T cells dominate the T cell repertoire in seropositive patients, 
particularly after chemotherapy [147, 148]. In spite of this, patient survival is 
reduced by almost 4 years in the CMV+ cohort. However, CMV+ CLL patients do 
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not exhibit symptoms of CMV-induced disease; the negative impact has been 
suggested to be due to CMV-specific T cell expansion constricting the overall T-
cell repertoire [149]. 
 Functionally, CD4+ and CD8+ T cells from CLL patients have been shown 
to secrete an increased amount of IL-4 [150]. IL-4 has been demonstrated to 
protect CLL B cells from apoptosis by upregulating the anti-apoptotic molecule 
Bcl-2 [151-153]. In addition, IL-4 producing CD8+ T cells from CLL patients show 
increased expression of CD30 [154]. The ligation of CD30L on the surface of CLL 
cells stimulates their production of TNF-α causing CLL cells to proliferate [154]. 
Also, binding to CD30L on the surface of CLL cells impairs isotype class 
switching and increases their sensitivity to FasL-mediated cell death [155]. 
Furthermore, expansion of CD4+CD25+ regulatory T cells (Tregs) may contribute 
to the immune defects in CLL. Number of Tregs is increased in CLL, mostly in 
patients with advanced disease [112, 156, 157]. Higher frequencies of Tregs have 
been shown to correlate with decreased T cell responses against viral and tumor 
antigens [112]. Tregs are also shown to decrease cellular immunity by soluble IL-2 
receptor (CD25) secretion, depriving T effector cells of IL-2 and therefore 
inhibiting anti-tumor T cell responses [158]. 
 Further functional defects in T cells from patients with CLL have been 
reported. A global gene expression profiling demonstrated that T cells from 
patients with CLL show a number of differentially expressed genes when 
compared with age-matched healthy donor T cells [50]. These altered genes 
were involved in cell differentiation and cytoskeletal formation in CD4+ T cells, 
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and cytoskeletal organization, vesicle trafficking and cytotoxicity pathways in 
CD8+ T cells [50]. Interestingly, these alterations in cytoskeletal formation 
pathways could be induced in healthy allogeneic T cells by co-culturing them with 
CLL cells, in a contact dependent manner [50]. In addition, these changes in the 
expression of cytoskeletal genes translated into a functional defect in actin 
polymerization, which caused the T cells from CLL patients to exhibit a defective 
immunologic synapse formation with antigen presenting cells [51]. These gene 
changes were comparable between T cells from the Eμ-TCL1 mouse and those 
from human CLL patients [111]. This work also revealed that CLL cells are the 
main driver for the changes in T cells, as introduction of malignant CLL cells into 
young and healthy Eμ-TCL1 animals induced the gene expression and functional 
defects similar to those seen in mice with frank leukemia [111]. Subsequent 
studies also demonstrated that the Eμ-TCL1 mouse accurately mimics the shift 
towards an antigen-experienced phenotype observed in human CLL disease 
[110]. 
(6b) Strategies to reconstitute the immune response in CLL 
 Reconstituting the immune response in CLL, especially T cell response, 
can provide many benefits to patients. According to the immune surveillance 
hypothesis, in order to present a clinically detectable disease, CLL cells must 
have evolved strategies for suppressing the immune system [138]. If we are able 
to restore the immune response to CLL, patients can have durable clinical 
responses. Also, T cells are known to provide help to B cells as part of their 
normal healthy function. They stimulate B cells to proliferate, induce B cell 
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antibody class switching and promote plasma cell differentiation [159]. In CLL, 
there is evidence that T cells have been skewed to provide help for the malignant 
B cells. Successful immune reconstitution should reduce the availability of T cell 
help to CLL, which could possibly lead to starvation of the CLL cells and 
apoptosis. Finally, as mentioned before infections are considered to be the 
leading cause of death in CLL. Therefore, immune reconstitution would help 
patients by enabling them to fight infections more effectively and possibly 
counteract the immune suppression induced by both the disease and current 
therapies.  
 In this dissertation work, I investigated the mechanisms underlying the 
immunosuppression induced by CLL as well as possible targets for the 
reconstitution of the immune response in CLL. During the course of my studies, I 
made the observation that splenic cells isolated from our CLL model, the Eμ-
TCL1 mouse, constitutively secreted IL-10. IL-10 is a well-known 
immunosuppressive cytokine, which has been shown to induce its effects on a 
number of immune cells including suppression of T cells. Initially, I found that 
neutralization of IL-10 using anti-IL-10 antibodies or anti-IL-10R antibody did not 
affect the survival or proliferation of the CLL cells in vitro despite the fact that IL-
10 receptor appears to be functional in CLL cells. On the other hand, I found that 
engraftment of CLL cells in comparison to WT mice was significantly lower in IL-
10R KO mice. IL-10 is known to inhibit the function of macrophages and 
monocytes by limiting their production of proinflammatory cytokines and 
chemokines, which could affect localization and survival of CLL cells in 
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microenvironmental niches. When I tested this possibility in our model, I found no 
significant difference of CLL cell migration between WT and IL-10R KO mice. 
However, this does not completely eliminate the effects of IL-10 on cells found in 
the CLL microenvironment. In preliminary data from our lab, we found that the 
spleen serves as a niche for CLL cell growth. Splenomegaly determined by 
ultrasound imaging, was observed in the CLL adoptive transfer model before CLL 
cells were detected in the peripheral blood. Current studies are investigating the 
unique stromal cells present in the spleen and their role in CLL growth. With 
finding such cells, we can further study the effects IL-10 might have on them. 
 Subsequently, I investigated the possible effects of IL-10 on T cell 
responses using our in vivo adoptive transfer model of CLL. Interestingly before 
this study, there was no direct evidence for involvement of CLL-derived IL-10 in T 
cell dysfunction. Here for the first time, I show a clear link between CLL-derived 
IL-10 and dysfunction of T cell responses to CLL cells. I demonstrated that T 
cells isolated from IL-10R KO mice primed with CLL proliferate and differentiate 
better than T cells isolated from an environment where IL-10 signaling was intact. 
In addition, injection of primed T cells along with CLL cells into NSG mice 
significantly reduced incidence of the disease. T cells from IL-10R KO mice were 
better than wild type T cells at controlling CLL growth.  
 Previous reports have shown contradictory results regarding the 
requirement of IL-10 for the survival and proliferation of B-CLL cells. Fluckiger et 
al reported that exogenous IL-10 inhibited the proliferation of human CLL cells 
and decreased the survival of CLL cells in culture by inducing apoptosis [160]. 
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They demonstrated that the addition of exogenous IL-10 to human CLL cells in 
culture decreased the viable cell recovery of the samples tested [160]. In 
addition, after one week in culture, cells cultured with IL-10 were completely lost 
while those cultured without IL-10 survived [160]. Finally, flow cytometric 
analysis, DNA gel electrophoresis, and Giemsa staining all revealed that IL-10 
induced death of CLL cells by apoptosis [160]. This observation is similar to 
normal B-1 cell regulation by IL-10, as we have demonstrated before that normal 
B-1 cell derived IL-10 inhibits their proliferation responses to TLR stimulation or 
BCR ligation [54, 73]. On the contrary, Kitabayashi et al reported that IL-10 
enhanced the survival of CLL cells in a dose dependent manner by preventing 
the apoptotic cell death of CLL cells [161]. This was also seen in a study, where 
IL-10 was required for the growth of a malignant B-1 cell clone, LNC, isolated 
from NZB mice and adapted for in vitro culture [162]. Although LNC was of B-1 
cell origin, it does not represent CLL, as LNC but not Eμ-TCL1 cells or human 
CLL cells undergo extensive proliferation in vitro. In my study both mouse and 
human CLL cells appear to be unique in not responding directly to IL10-mediated 
suppressive effects in vitro but that IL-10 affects CLL growth indirectly by 
suppressing anti-CLL T cells. 
(6c) Multiple immunosuppression mechanisms in CLL  
 The question then remains of why T cells in the de novo CLL disease do 
not completely control disease development. T cells isolated from CLL patients 
have been found to have higher expression of checkpoint molecules such as 
cytotoxic T-lymphocyte-associated protein- 4 (CTLA-4) and programmed cell 
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death protein-1 (PD-1) [163, 164]. This possibility of multiple pathways of 
immunosuppression raises the need for combination therapy to target multiple 
modulators of immune suppression. For example, the use of anti-IL-10 and 
checkpoint inhibitors should be considered, however, this could only be useful in 
tumors that produce IL-10 such as CLL and other B-lymphomas known for their 
IL-10 production. This also alludes to the fact that careful investigation of 
changes due to immunotherapy drugs such as changes in the expression pattern 
of cytokines, chemokines, tumor antigens, and other immune-related factors 
should be considered as they could provide answers to some of the 
compensatory immunosuppressive mechanisms that could be targeted by 
combination therapy. Indeed, future studies need to investigate other cytokines 
produce by CLL cells and their role in either CLL growth or immune responses to 
CLL. Surprisingly, there are only few studies that explore cytokines and 
chemokines produced by CLL cells themselves. Notably, the production of IL-6 
has been investigated in the context of CLL. One study examined the correlation 
between serum IL-6 and IL-10 levels and outcome in CLL [165]. The levels of IL-
6 and IL-10 were higher in CLL patients compared to healthy individuals [165]. 
They also found that cytokine levels correlated with clinical features and survival 
[165]. Similar to the inconsistent results found in literature about the role of IL-10 
in CLL growth, IL-6 shares the same problem. In an opposing study, authors 
demonstrated that the addition of recombinant human IL-6 significantly 
decreased the TNF-induced CLL growth [166]. Therefore according to this study, 
IL-6 is not a growth stimulatory factor but an effective inhibitor of the TNF-
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induced proliferation of the leukemic B-CLL cells [166]. Another cytokine 
produced by CLL cells, which is worth noting, is TGF-β. CLL B cells have been 
found to overexpress TGF-β, in which it functions as an autocrine growth inhibitor 
possibly accounting for the reduced proliferative responses of these leukemic 
cells to different stimuli, such as anti-IgM and anti-CD40 stimulation [53]. 
(6d) T cell adoptive transfer for the therapy of CLL 
 As seen from data in chapter 4, the transfer of primed T cells in 
combination with CLL cells into immunodeficient mice significantly delayed CLL 
disease progression, whereas T cells from IL-10R KO mice were able to 
completely abrogate disease. In fact, NOG mice injected with a ratio of 1 T cell 
(from primed IL-10R KO mice) to 16 CLL cells showed no sign of CLL even after 
150 days post injection, showing promise for long-term effectiveness. 
Interestingly, CD8+ T cells were sufficient in delaying CLL disease development 
and CD8+ T cells isolated from IL-10R KO primed with CLL were significantly 
better at controlling CLL growth than CD8+ T cells isolated from WT mice. Re-
challenging experiments will be done in the future to investigate if memory T cells 
are still present in these mice. This is such an important observation, as the idea 
of T cell adoptive transfer in treating a number of cancers has been a hot topic of 
immunotherapy in the recent years. Specifically, chimeric antigen receptor (CAR) 
T cell therapy has been an interesting area of investigation. It is the adoptive 
transfer of T cells with specificity to tumor antigens. There are two main 
strategies for generating tumor-specific T cells. The first involves gene transfer of 
TCRs with known specificity into autologous or allogeneic T cells, which are then 
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expanded in vitro and infused into patients [167]. This approach has seen some 
success in melanoma and in the use of T cells specific to Epstein-Barr virus to 
treat posttransplant lymphoproliferative disorders [168-170]. The challenge with 
this approach is the fact that recognition of tumor antigens is MHC-restricted, so 
the use of these T cells must be individualized to each patient according to their 
MHC type. Also, with this approach there is a risk that a subunit of the transgenic 
TCR could associate with an endogenous TCR, which leads to changing the 
specificity of the T cell possibly leading to autoimmunity. The second strategy 
uses an antibody-derived antigen binding part, usually a single chain variable 
fragment, fused with an internal signaling domain such as CD3ζ to form a 
chimeric antigen receptor or CAR [171, 172]. This strategy eliminates MHC 
restriction, enabling the same CAR to be used in different patients. In addition, 
the use of an antibody receptor allows the potential targets to include a variety of 
surface proteins, sugars and lipids [172]. Nevertheless, the choice of these 
targets for CARs must be selected carefully in which the antigen is not also 
expressed on normal nonmalignant tissues [172]. In the context of CLL, a 
number of targets have the potential to be used for CAR development; those 
include CD19, CD20, CD23 and receptor tyrosine kinase-like orphan receptor 1 
(ROR1). CLL B cells express high levels of CD19 and relatively reduced 
expression of CD20. However, these molecules are also expressed by normal B 
cells, so CAR T cells targeting them will also eliminate normal B cells, causing 
impaired humoral immunity worsening the immunodeficiency already seen in CLL 
patients [173]. Anti-ROR1 CAR CD8+ T cells have been successfully generated 
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from patients with CLL [174]. ROR1 has the advantage of being selectively 
expressed by malignant B cells, although it is also expressed by undifferentiated 
embryonic stem cells and in adipose tissue at low levels [174]. Likewise, anti-
CD23 CAR T cells generated from CLL patients have shown cytotoxicity against 
autologous and allogeneic CLL cells as well as in vivo antitumor effect in a 
xenograft murine model [175]. Currently, there are a number of phase 1 and 2 
clinical trials utilizing anti-CD19 CAR T cells for the treatment of B cell 
malignancies [172]. In preclinical studies, anti-CD19 CAR T cells were able to 
effectively lyse a broad panel of human CD19+ tumor cell lines and primary 
malignant B cells, in addition to demonstrating anti-lymphoma effects in a murine 
model [176, 177]. In a specific clinical trial, a group treated eight patients with 
relapsed CLL in two cohorts [178]. The first cohort had three patients who were 
treated without cyclophosphamide conditioning and showed no response [178]. 
The second cohort was treated with cyclophosphamide conditioning with a 
reduced dose of T cells. Three of these patients showed disease stabilization or 
lymph node responses [178]. In addition, this cohort showed some persistence of 
the anti-CD19 CAR T cells, which were detectable by immunohistochemistry in 
bone marrow up to 2 months after infusion [178]. This trial has pointed out the 
importance of the conditioning regimen in promoting T cell engraftment and 
activation. For instance, it may be important to eliminate Tregs, which are known 
to be expanded in CLL as well as eliminating other cell populations such as 
immature dendritic cells and any cell populations that could compete for the 
same survival and stimulatory cytokines as those T cells [156, 173]. Adoptive 
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transfer of anti-CD19 CAR T cells is a promising new approach for treating CLL. 
However, future studies will need to further identify CLL antigens that are 
recognized by T cells, which could possibly be utilized in developing new CAR T 
cell therapy for CLL. A recent study has shown promise in this area in which they 
were able to analyze the landscape of naturally presented HLA class I and II 
ligands of primary CLL, in which a novel category of tumor-associated T-cell 
antigens were identified [179]. Specific expression of these HLA ligands 
exclusively in CLL patients correlated with the frequencies of immune recognition 
by patient T cells [179]. In addition, patients displaying immune responses to 
multiple antigens exhibited better survival than those with responses to one or 
fewer antigens [179]. 
(6e) Molecular Mechanisms involved in IL-10 production 
 The fact that IL-10 was found to inhibit T cell responses to CLL makes it 
an attractive target for enhancement of this anti-CLL immune response as seen 
in our mouse model, where the lack of IL-10 signaling caused an increase in T 
cell activity and a reduction in engraftment of CLL. Unfortunately, therapy using 
anti-IL-10 or anti-IL-10R antibodies has not been successful in human patients 
[180]. This is due to the fact that IL-10 plays such an important role in regulating 
a wide range of immune cells. Manipulation of IL-10 must be balanced carefully 
to enhance anti-tumor responses but with the need to minimize host tissue 
damage. Importantly, the pleiotropic effect of IL-10 on different cell-types must 
also be considered, as the function of various immune cells may be up or down 
regulated simultaneously. Therefore, I aimed to understand the specific 
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molecular events that regulate the production of IL-10, which can help in 
designing new strategies of immune intervention. A previous study has found that 
BAFF stimulation via TACI receptor enhanced IL-10 production by leukemic B 
cells in CLL patients and Eμ-TCL1 mice [96]. Another study demonstrated an 
epigenetic control of IL-10 production, in which differential IL-10 gene methylation 
was responsible for the variability of IL-10 production by human CLL cells [97]. 
My studies demonstrated a novel role of BCR signaling in the constitutive 
production of IL-10. Since BCR signaling is important in CLL subtypes such as U-
CLL, BCR-induced IL-10 could be a factor in their more aggressive nature.  I 
found that inhibition of BCR signaling led to a decrease in ERK1/2 MAP kinase 
activation, which is consistent with a role for ERK1/2 in IL-10 production seen in 
T cells [84]. BCR signaling mediated IL-10 production was STAT3 independent. 
Moreover, a novel role for the transcription factor Sp1 in BCR signaling 
dependent IL-10 production by CLL cells is described here. Sp1 bound to the IL-
10 promoter in CLL cells and inhibition of Sp1 led to a decrease in IL-10 
production in a dose dependent manner. I was also able to link the activation of 
ERK1/2 to Sp1 activity, which is consistent with regulation of Sp1 by ERK1/2 in 
other cell types [131, 181]. My results introduce a new rationale to therapeutics 
targeting the ERK-Sp1 pathway. 
 In this study I utilized Mithramycin A as the Sp1 inhibitor [128]. 
Mithramycin A is an antitumor compound produced by Streptomyces argillaceus 
that has been used for the treatment of several types of tumors [128]. 
Mithramycin A is a DNA binding agent with relative specificity for Sp1 [182]. Its 
  121 
 
mode of action involves its interaction in a noncovalent way with GC-rich DNA 
regions located in the minor groove of DNA [182]. By doing so, it prevents Sp1 
from binding to a variety of promoters [182]. It was discovered in 1961 and 
approved for use as anticancer drug in 1970 [182]. However, despite showing 
strong response rates, it has not been in use in recent years due to its adverse 
effects. Mithramycin A has a limited therapeutic window because active doses 
cause toxic effects [182]. Fortunately, the development of a number of 
derivatives of Mithramycin A is underway [182, 183]. So, future studies need to 
investigate some of these derivatives and their effects on IL-10 production, in 
which they could be possibly utilized in animal experiments as well as human 
clinical trials with limited side effects. 
 In addition to development of new therapeutic targets for IL-10 production, 
studies need to be performed to study the effects of currently used therapies in 
CLL. For example, BCR signaling inhibitors, such as ibrutinib have been FDA 
approved and widely used in the treatment of CLL. Ibrutinib was found to 
enhance antitumor immune responses induced by intratumoral injection of CpG 
in a mouse lymphoma model as well as to enhance generation of CAR T-cells for 
adoptive immunotherapy [184, 185]. My finding that ibrutinib inhibits IL-10 
production by CLL cells provides a potential mechanism by which ibrutinib 
treatment is enhancing anti-tumor immunity. This mechanism is likely to extend 
to other BCR signaling inhibitors such as fostamatinib and idelalisib.  
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Summary and future directions 
 The study presented here demonstrates that CLL derived IL-10 promotes 
immunosuppression utilizing BCR signaling, a key mechanism for the survival of 
B cells, for its regulation (Figure 6.1). I also found that CLL derived IL-10 inhibits 
T cell responses to CLL allowing for the rapid growth of CLL (Figure 6.1). Hence 
the inhibition of IL-10 pathway could be used to restore anti-tumor immunity. For 
future studies, several ideas need to be explored: 
 
1. T cells had a robust effect in controlling the development of CLL cells in 
our adoptive transfer mouse model, however, T cells in the de novo CLL 
disease do not completely control disease development. There is a higher 
expression of checkpoint molecules such as PD-1 and CTLA-4 on T cells 
isolated from CLL patients. Therefore, the use of anti-IL-10 and checkpoint 
inhibitors could be useful in tumors that produce IL-10 such as CLL. 
2. Further investigation of other immunosuppressive mechanisms in CLL 
should be done, as it could provide answers to some of the compensatory 
immunosuppressive mechanisms that could be targeted by combination 
therapy. 
3. During my T cell adoptive transfer experiments; T cells were able to 
completely prevent the development of CLL in a number of mice. Re-
challenging experiments will help investigate if memory T cells are present 
in these mice.  
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4. Although I was able to observe anti-CLL tumor response by T cells, future 
studies need to explore the identity of these T cells. Expansion of specific 
type of T cells can allow us to find out the CLL antigens that are 
recognized by these T cells and therefore generate new CAR T cells for 
the treatment of CLL. 
5. BCR signaling played a significant role in the production of IL-10 by CLL 
cells via the ERK1/2-Sp1 pathway. Another potential for combination 
therapy is the use of Sp1 inhibitors with current approved therapy to test 
the synergistic or additive effects it might have on disease development.      
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Figure 6.1: Mechanistic model of IL-10 production by CLL cells and IL-10 
effects on T cell responses 
BCR signaling controls IL-10 production by activation of the Syk-ERK1/2-Sp1 
signaling pathway. IL-10 inhibits IFN-γ production by T cells leading to the 
inhibition of anti-tumor immunity and the rapid growth of CLL cells. 
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 APPENDIX A 
List of Abbreviations 
NHLs - Non-Hodgkins lymphomas 
CLL - Cell Chronic Lymphocytic Leukemia 
DLBCL – diffuse large B-cell lymphoma 
BCR - B cell receptor 
IGVH - immunoglobulin variable heavy chain 
U-CLL - Unmutated IGHV CLL 
M-CLL - Mutated IGHV CLL 
BTK - Bruton tyrosine kinase 
PI3K - Phosphoinositide 3-kinase 
BCL-2 - B-cell lymphoma 2 
GC - Germinal center 
MZ - Marginal Zone 
AMyIIA - Non-muscle myosin IIA 
IL-2 - Interleukin-2 
Th - T helper 
TNF- α - Tumor necrosis factor alpha 
PD-1 - Programmed death-1 
TGF- β - Transforming growth factor beta 
IL-10 - Interleukin-10 
LT-α - Lymphotoxin alpha 
IFN-γ - Interferon gamma 
  126 
 
UC - Ulcerative colitis 
EAE - Experimental autoimmune encephalomyelitis 
Bregs - regulatory B cells 
MS - Multiple sclerosis 
DCs - Dendritic cells 
TLR - Toll like receptor 
CSIF - Cytokine synthesis inhibitory factor 
IL-10R - IL-10 receptor 
STAT3 - Signal transducer and activator of transcription 3 
ERK - Extracellular signal regulated kinase 
MYD88 - Myeloid differentiation primary-response protein 88 
TRIF - TIR-domain-containing adaptor protein inducing IFNβ 
NF-κB - Nuclear factor-κB 
DC-SIGN - DC-specific ICAM3-grabbing non-integrin 
Syk - Spleen tyrosine kinase 
NOD2 - Nucleotide-binding oligomerization domain 2 
TCR - T cell receptor 
FOXP3 - Forkhead box P3 
TReg - T regulatory 
Sp1 - Specific protein 1 
C/EBPβ - CCAAT/enhancer binding protein-β 
IRF1 - IFN-regulatory factor 1 
BAFF - B-cell-activating factor of the tumor necrosis factor family 
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TACI - Transmembrane activator and cyclophilin ligand interactor 
TCL1 - T-cell leukemia oncogene 1 
IL-10R KO - B6.129S2-Il10rbtm1Agt/J 
NOG - NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac 
IACUC - Institutional Animal Care and Use Committee 
BCS - Body condition score 
FBS - Fetal Bovine Serum  
IMDM - Iscove's Modified Dulbecco's Medium 
MTT - Thiazolyl Blue Tetrazolium Bromide 
PBS - Phosphate buffered saline 
CFSE - Carboxyfluorescein succinimidyl ester 
HBSS - Hank’s buffered salt solution 
ELISA - Enzyme-linked immunosorbent assay 
OD - Optical Density 
BCA - Bicinchoninic Acid 
SDS - Sodium dodecyl sulfate 
GAPDH - Glyceraldehyde 3-phosphate dehydrogenase 
qRT-PCR - Quantitative Real-Time PCR 
shRNA - Short hairpin RNA 
CHIP - Chromatin Immunoprecipitation 
H&E - hematoxylin and eosin 
WT - Wild type 
NK - Natural killer 
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PB - Peripheral blood 
BM - Bone marrow 
PC - Peritoneal cavity 
PBMCs - Peripheral blood mononuclear cells 
JNK1 - c-Jun NH(2)-terminal kinase 1 
AIDS - acquired immune deficiency syndrome 
CMV - cytomegalovirus 
CTLA-4 cytotoxic T-lymphocyte-associated protein- 4 
CAR - chimeric antigen receptor 
ROR-1 - receptor tyrosine kinase-like orphan receptor 1 
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